

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 April 2007 (12.04.2007)

PCT

(10) International Publication Number
WO 2007/040436 A1

(51) International Patent Classification:

A61K 31/506 (2006.01) A61P 25/28 (2006.01)
A61P 19/08 (2006.01) A61P 3/10 (2006.01)
A61P 25/16 (2006.01) C07D 401/14 (2006.01)
A61P 25/18 (2006.01) C07D 403/04 (2006.01)
A61P 25/24 (2006.01)

(74) Agent: ASTRAZENECA; Global Intellectual Property,
S-151 85 Södertälje (SE).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number:

PCT/SE2006/001112

(22) International Filing Date: 2 October 2006 (02.10.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0502177-9 3 October 2005 (03.10.2005) SE

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **ANDERSSON, Lars** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **BERG, Stefan** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **BURROWS, Jeremy** [GB/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **HELLBERG, Sven** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **HUERTA, Fernando** [ES/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **REIN, Tobias** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER'S DISEASE



(I)

(57) Abstract: The present invention relates to a new use of pyrimidine derivatives of formula I, as a free base or a pharmaceutically acceptable salt thereof in the manufacture of a medicament in the treatment and/or prophylaxis of Alzheimer's Disease:

WO 2007/040436 A1

Use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of Alzheimer's disease.

TECHNICAL FIELD OF INVENTION

The present invention relates to a new use of pyrimidine derivatives, as a free base or a pharmaceutically acceptable salt thereof in the manufacture of a medicament in the treatment and/or prophylaxis of conditions associated with glycogen synthase kinase-3.

The present invention further relates to a method of treatment and/or prophylaxis of conditions associated with glycogen synthase kinase-3, comprising administering to a mammal, including man in need of such prevention and/or prophylaxis a therapeutically effective amount of said pyrimidine derivatives. In addition, the present invention relates to new compounds suitable for the inhibition of glycogen synthase kinase-3.

BACKGROUND OF THE INVENTION

Glycogen synthase kinase 3 (GSK3) is a serine / threonine protein kinase composed of two isoforms (α and β), which are encoded by distinct genes but are highly homologous within the catalytic domain. GSK3 is highly expressed in the central and peripheral nervous system. GSK3 phosphorylates several substrates including tau, β -catenin, glycogen synthase, pyruvate dehydrogenase and elongation initiation factor 2b (eIF2b). Insulin and growth factors activate protein kinase B, which phosphorylates GSK3 on serine 9 residue and inactivates it.

Alzheimer's Disease (AD) dementias, and taupathies

AD is characterized by cognitive decline, cholinergic dysfunction and neuronal death, neurofibrillary tangles and senile plaques consisting of amyloid- β deposits. The sequence of these events in AD is unclear, but they are believed to be related. Glycogen synthase kinase 3 β (GSK3 β) or Tau (τ) phosphorylating kinase selectively phosphorylates the microtubule associated protein τ in neurons at sites that are hyperphosphorylated in AD brains. Hyperphosphorylated protein τ has lower affinity for microtubules and accumulates as paired helical filaments, which are the main components that constitute neurofibrillary tangles and neuropil threads in AD brains. This results in depolymerization of microtubules, which leads to dying back of axons and neuritic dystrophy. Neurofibrillary tangles are consistently found in diseases such as AD, amyotrophic lateral sclerosis,

parkinsonism-dementia of Gaum, corticobasal degeneration, dementia pugilistica and head trauma, Down's syndrome, postencephalatic parkinsonism, progressive supranuclear palsy, Niemann-Pick's Disease and Pick's Disease. Addition of amyloid- β to primary hippocampal cultures results in hyperphosphorylation of τ and a paired helical filaments-like state via induction of GSK3 β activity, followed by disruption of axonal transport and neuronal death (Imahori and Uchida., J. Biochem 121:179-188, 1997). GSK3 β preferentially labels neurofibrillary tangles and has been shown to be active in pre-tangle neurons in AD brains. GSK3 protein levels are also increased by 50% in brain tissue from AD patients. Furthermore, GSK3 β phosphorylates pyruvate dehydrogenase, a key enzyme in the glycolytic pathway and prevents the conversion of pyruvate to acetyl-Co-A (Hoshi et al., PNAS 93:2719-2723, 1996). Acetyl-Co-A is critical for the synthesis of acetylcholine, a neurotransmitter with cognitive functions. Thus, GSK3 β inhibition may have beneficial effects in progression as well as the cognitive deficits associated with Alzheimer's disease and other above-referred to diseases.

Chronic and Acute Neurodegenerative Diseases

Growth factor mediated activation of the PI3K /Akt pathway has been shown to play a key role in neuronal survival. The activation of this pathway results in GSK3 β inhibition. Recent studies (Bhat et. al., PNAS 97:11074-11079 (2000)) indicate that GSK3 β activity is increased in cellular and animal models of neurodegeneration such as cerebral ischemia or after growth factor deprivation. For example, the active site phosphorylation was increased in neurons vulnerable to apoptosis, a type of cell death commonly thought to occur in chronic and acute degenerative diseases such as Alzheimer's Disease, Parkinson's Disease, amyotrophic lateral sclerosis, Huntington's Disease and HIV dementia, ischemic stroke and head trauma. Lithium was neuroprotective in inhibiting apoptosis in cells and in the brain at doses that resulted in the inhibition of GSK3 β . Thus GSK3 β inhibitors could be useful in attenuating the course of neurodegenerative diseases.

Bipolar Disorders (BD)

Bipolar Disorders are characterised by manic episodes and depressive episodes. Lithium has been used to treat BD based on its mood stabilising effects. The disadvantage of lithium is the narrow therapeutic window and the danger of overdosing that can lead to lithium intoxication. The recent discovery that lithium inhibits GSK3 at therapeutic concentrations has raised the possibility that this enzyme represents a key target of lithium's action in the brain (Stambolic et al., Curr. Biol. 6:1664-1668, 1996; Klein and Melton; PNAS 93:8455-8459, 1996). Inhibition of GSK3 β may therefore be of therapeutic relevance in the treatment of BD as well as in AD patients that have affective disorders.

Schizophrenia

GSK3 is involved in signal transduction cascades of multiple cellular processes, particularly during neural development. Kozlovsky et al (Am J Psychiatry 2000 May;157(5):831-3) found that GSK3 β levels were 41% lower in the schizophrenic patients than in comparison subjects. This study indicates that schizophrenia involves neurodevelopmental pathology and that abnormal GSK3 regulation could play a role in schizophrenia. Furthermore, reduced β -catenin levels have been reported in patients exhibiting schizophrenia (Cotter et al., Neuroreport 9:1379-1383 (1998)).

Diabetes

Insulin stimulates glycogen synthesis in skeletal muscles via the dephosphorylation and thus activation of glycogen synthase. Under resting conditions, GSK3 phosphorylates and inactivates glycogen synthase via dephosphorylation. GSK3 is also over-expressed in muscles from Type II diabetic patients (Nikoulina et al., Diabetes 2000 Feb;49(2):263-71). Inhibition of GSK3 increases the activity of glycogen synthase thereby decreasing glucose levels by its conversion to glycogen. GSK3 inhibition may therefore be of therapeutic relevance in the treatment of Type I and Type II diabetes and diabetic neuropathy.

Hair Loss

GSK3 phosphorylates and degrades β -catenin. β -catenin is an effector of the pathway for keratin synthesis. β -catenin stabilisation may lead to increase hair development. Mice expressing a stabilised β -catenin by mutation of sites phosphorylated by GSK3 undergo a

process resembling de novo hair morphogenesis (Gat et al., Cell 1998 Nov 25;95 (5):605-14)). The new follicles formed sebaceous glands and dermal papilla, normally established only in embryogenesis. Thus GSK3 inhibition may offer treatment for baldness.

5 *Oral contraceptives*

Vijayaraghavan et al. (Biol Reprod 2000 Jun; 62 (6):1647-54) reported that GSK3 is high in motile versus immotile sperm. Immunocytochemistry revealed that GSK3 is present in the flagellum and the anterior portion of the sperm head. These data suggest that GSK3 could be a key element underlying motility initiation in the epididymis and regulation of
10 mature sperm function. Inhibitors of GSK3 could be useful as contraceptives for males.


Bone-related disorders

It has been shown that GSK3 inhibitors could be used for treatment of bone-related disorders. This has been discussed in e.g. Tobias et al., *Expert Opinion on Therapeutic
15 Targets*, Feb 2002, pp 41-56.

DISCLOSURE OF THE INVENTION

The object of the present invention is to provide the use of compounds having a selective inhibiting effect at GSK3 as well as having a good bioavailability.

20 The present invention relates to the use of a compound of formula I,



wherein

R¹ is selected from hydrogen, halo, CN, NO₂, C₁₋₃alkyl, C₁₋₃haloalkyl, OR^a, SO₂NR^bR^c,
25 C(O)NR^bR^c, CH₂NR^bR^c, CH₂OR^h, SO₂Rⁱ and C(O)R^j;

R^2 and R^4 are independently selected from hydrogen, halo, CN, NO_2 , C_{1-3} alkyl, C_{1-3} haloalkyl, OR^a , $\text{SO}_2\text{NR}^b\text{R}^c$, $\text{C}(\text{O})\text{NR}^b\text{R}^c$, $\text{CH}_2\text{NR}^b\text{R}^c$, CH_2OR^h , SO_2R^i and $\text{C}(\text{O})\text{R}^j$;

R^3 and R^5 independently are selected from hydrogen, C_{1-3} alkyl, C_{1-3} haloalkyl and OR^a ;

R^6 is selected from C_{2-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, and C_{2-4} haloalkyl;

5 R^7 is selected from C_{1-3} alkyl, CN, and C_{1-3} haloalkyl, said C_{1-3} alkyl or C_{1-3} haloalkyl optionally substituted with one or more OR^a ;

R^8 and R^9 are independently selected from hydrogen, CN and halo;

R^a is hydrogen, C_{1-3} alkyl or C_{1-3} haloalkyl, said C_{1-3} alkyl or C_{1-3} haloalkyl optionally substituted with one or more C_{1-3} alkoxy;

10 R^b and R^c are independently selected from hydrogen, C_{1-6} alkyl or C_{1-6} haloalkyl, said C_{1-6} alkyl or C_{1-6} haloalkyl optionally substituted with one or more OR^a or NR^dR^e ; or

R^b and R^c may, together with the atom to which they are attached, form a 4-, 5- or 6-membered heterocyclic ring containing one or more heteroatoms selected from N, O or S, wherein said heterocyclic ring is optionally substituted with one or more halo, C_{1-3} alkyl or C_{1-3} haloalkyl, said C_{1-3} alkyl or C_{1-3} haloalkyl optionally further substituted with one or
15 more C_{1-3} alkoxy;

R^d and R^e are independently selected from hydrogen, C_{1-6} alkyl or C_{1-6} haloalkyl, said C_{1-6} alkyl or C_{1-6} haloalkyl optionally substituted with one or more OR^a ; or

R^d and R^e may, together with the atom to which they are attached, form a 4-, 5- or 6-membered heterocyclic ring containing one or more heteroatoms selected from N, O or S, wherein said heterocyclic ring is optionally substituted with one or more halo, C_{1-3} alkyl or C_{1-3} haloalkyl, said C_{1-3} alkyl or C_{1-3} haloalkyl optionally further substituted with one or
20 more C_{1-3} alkoxy;

R^h is hydrogen, C_{1-3} alkyl or C_{1-3} haloalkyl, said C_{1-3} alkyl or C_{1-3} haloalkyl optionally
25 substituted with one or more C_{1-3} alkoxy;

R^i is C_{1-3} alkyl or C_{1-3} haloalkyl, said C_{1-3} alkyl or C_{1-3} haloalkyl optionally substituted with one or more OR^a ; and

R^j is an aryl or heteroaryl ring, wherein said aryl or heteroaryl ring is optionally substituted with one or more C₁₋₃alkyl, OR^a, halo or CN;
or a pharmaceutically acceptable salt thereof for use in the manufacturing of a medicament for prevention and/or treatment of Alzheimer's Disease.

5

One embodiment of the present invention relates to the use of a compound according to formula **I**, wherein

R¹ is selected from hydrogen, SO₂NR^bR^c, C(O)NR^bR^c, CH₂NR^bR^c and C(O)Rⁱ;

R² and R⁴ are independently selected from hydrogen, halo, CN, C₁₋₃alkyl, OR^a, and SO₂Rⁱ;

10 R³ and R⁵ independently are selected from hydrogen, C₁₋₃alkyl, C₁₋₃haloalkyl;

R⁶ is selected from C₂₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, and C₂₋₄haloalkyl;

R⁷ is C₁₋₃alkyl;

R⁸ and R⁹ are independently selected from hydrogen and halo; and

15 R^a is C₁₋₃alkyl or C₁₋₃haloalkyl, said C₁₋₃alkyl or C₁₋₃haloalkyl optionally substituted with one or more C₁₋₃alkoxy;

R^b and R^c are independently selected from hydrogen, C₁₋₆alkyl or C₁₋₆haloalkyl, said C₁₋₆alkyl or C₁₋₆haloalkyl optionally substituted with one or more OR^a; or

20 R^b and R^c may, together with the atom to which they are attached, form a 4-, 5- or 6-membered heterocyclic ring containing one or more heteroatoms selected from N, O or S, wherein said heterocyclic ring is optionally substituted with one or more halo, C₁₋₃alkyl or C₁₋₃haloalkyl, said C₁₋₃alkyl or C₁₋₃haloalkyl optionally further substituted with one or more C₁₋₃alkoxy;

Rⁱ is C₁₋₃alkyl; and

R^j is aryl or heteroaryl;

25 or a pharmaceutically acceptable salt thereof.

Another embodiment of the present invention relates to the use of a compound according to formula **I**, wherein

R^1 is selected from $SO_2NR^bR^c$, $C(O)NR^bR^c$ and $C(O)R^i$;

R^2 and R^4 are independently selected from hydrogen, halo, CN, C_{1-3} alkyl, OR^a , and SO_2R^i ;

R^3 and R^5 independently are selected from hydrogen, C_{1-3} alkyl, C_{1-3} haloalkyl;

R^6 is C_{2-4} alkyl;

5 R^7 is C_{1-3} alkyl;

R^8 and R^9 are independently selected from hydrogen and halo;

R^a is C_{1-3} alkyl or C_{1-3} haloalkyl;

R^b and R^c may, together with the atom to which they are attached, form a 4-, 5 or 6-membered heterocyclic ring containing one or more heteroatoms selected from N, O or S,

10 wherein said heterocyclic ring is optionally substituted with one or more C_{1-3} alkyl;

R^i is C_{1-3} alkyl; and

R^j is aryl or heteroaryl;

or a pharmaceutically acceptable salt thereof.

15 Yet another embodiment of the present invention relates to the use of a compound according to formula I, wherein R^9 is halo and R^8 is hydrogen.

A further embodiment of the present invention relates to the use according to claim 4, wherein R^9 is fluoro.

20

Another embodiment of the present invention relates to the use of a compound according to formula I, wherein R^6 is C_{2-4} alkyl. According to one embodiment of the present invention, R^6 is isopropyl.

25 One embodiment of the present invention relates to the use of a compound according to formula I, wherein R^7 is fluoromethyl or methyl.

Another embodiment of the present invention provides the use of a compound according to formula I, wherein R^2 and R^4 are hydrogen.

Yet another embodiment of the present invention relates to the use of a compound according to formula I, wherein R^5 and R^3 are hydrogen.

- 5 One embodiment of the present invention provides the use of a compound according to formula I, wherein R^1 is selected from $C(O)NR^bR^c$, $SO_2R^bR^c$, SO_2R^i or $C(O)R^j$. According to one embodiment of the present invention, R^j is phenyl or piperidin. According to another embodiment of the present invention, R^b and R^c , together with the atom to which they are attached, form a 6-membered heterocyclic ring containing one or more
- 10 heteroatoms selected from N, wherein said heterocyclic ring is optionally substituted with one or more halo, C_{1-3} alkyl or C_{1-3} haloalkyl. According to a further embodiment of the present invention, said heterocyclic ring is substituted with one or more C_{1-3} alkyl. According to yet a further embodiment of the present invention, said C_{1-3} alkyl is methyl. According to another embodiment of the present invention, R^i is C_{1-3} alkyl. According to
- 15 yet another embodiment of the present invention, R^i is methyl,

The present invention also relates to the use of a compound of formula I, in the manufacturing of a medicament for the treatment and/or prophylaxis of conditions associated with glycogen synthase kinase-3 inhibition, said compound being selected from:

- 20 (4- {[5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-yl]amino}phenyl)(phenyl)methanone hydrochloride;
(4- {[5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-yl]amino}phenyl)(pyridin-2-yl)methanone hydrochloride;
(4- {[5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-yl]amino}phenyl)(pyridin-3-yl)methanone hydrochloride;
- 25 5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-*N*-{3-methyl-4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrimidin-2-amine hydrochloride;
5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-*N*-{2-methyl-4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrimidin-2-amine hydrochloride;
- 30 5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-*N*-[4-[(4-methylpiperazin-1-yl)sulfonyl]-2-(trifluoromethyl)phenyl]pyrimidin-2-amine hydrochloride;

5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-*N*-[4-[(4-methylpiperazin-1-yl)sulfonyl]-3-(trifluoromethoxy)phenyl]pyrimidin-2-amine hydrochloride;
 5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-*N*-[4-[(4-methylpiperazin-1-yl)carbonyl]-3-(methylsulfonyl)phenyl]pyrimidin-2-amine hydrochloride;
 5-{{[5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-yl]amino}-2-[(4-methylpiperazin-1-yl)carbonyl]benzonitrile hydrochloride;
N-{3-Chloro-4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}-5-fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-amine hydrochloride;
 5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-*N*-{3-methoxy-4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}pyrimidin-2-amine hydrochloride;
 (4-{{[5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-yl]amino}phenyl)(pyridin-4-yl)methanone hydrochloride;
 5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-*N*-{4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}pyrimidin-2-amine hydrochloride;
 5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-*N*-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrimidin-2-amine hydrochloride;
 5-Fluoro-4-[1-isopropyl-2-(trifluoromethyl)-1*H*-imidazol-5-yl]-*N*-[4-(methylsulfonyl)phenyl]pyrimidin-2-amine hydrochloride;
 5-Fluoro-4-[1-isopropyl-2-(trifluoromethyl)-1*H*-imidazol-5-yl]-*N*-[4-(methylsulfonyl)phenyl]pyrimidin-2-amine hydrochloride;
 {4-[5-Fluoro-4-(3-isopropyl-2-trifluoromethyl-3*H*-imidazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone hydrochloride; and
 3-{{[5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-yl]amino}-*N*-(3-methoxypropyl)benzamide hydrochloride;
 or a pharmaceutically acceptable salt thereof.

According to one aspect of the present invention, there is provided the use of a compound of formula **I** as a free base or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment and/or prophylaxis of conditions associated with GSK3.

According to another aspect of the present invention, there is provided a method of treatment and/or prophylaxis of conditions associated with GSK3 comprising

administering to a mammal, including man in need of such treatment and/or prophylaxis a therapeutically effective amount of a compound of formula I as a free base or a pharmaceutically acceptable salt thereof.

5 According to yet another aspect of the present invention, there is provided a pharmaceutical formulation for use in the treatment and/or prophylaxis of conditions associated with GSK3 comprising a therapeutically effective amount of a compound of formula (I) as a free base or a pharmaceutically acceptable salt thereof and conventional excipients.

10

It has now surprisingly been found that the group of pyrimidine derivatives as described below are well suited for inhibiting glycogen synthase kinase-3. The use of said glycogen synthase kinase-3 inhibitors are suitable in the treatment and/or prophylaxis of conditions associated with especially, dementia, Alzheimer's Disease, Parkinson's Disease,
15 Frontotemporal dementia Parkinson's Type, Parkinson dementia complex of Guam, HIV dementia, diseases with associated neurofibrillar tangle pathologies, amyotrophic lateral sclerosis, corticobasal degeneration, dementia pugilistica, Down's syndrome, Huntington's Disease, postencephalatic parkinsonism, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, stroke, head trauma and other chronic neurodegenerative
20 diseases, Bipolar Disease, affective disorders, depression, schizophrenia, cognitive disorders, Type I and Type II Diabetes and Diabetic neuropathy, hair loss, contraceptive medication and bone disorder.

Listed below are definitions of various terms used in the specification and claims to
25 describe the present invention.

In this specification the term "alkyl" includes both straight and branched chain as well as cycloalkyl groups. The term C₁₋₃alkyl having 1 to 3 carbon atoms and may be, but is not limited to, methyl, ethyl, *n*-propyl, *i*-propyl, or cyclopropyl. The term C₂₋₄alkyl having 2 to
30 4 carbon atoms and may be, but is not limited to, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *i*-butyl, *s*-butyl, *t*-butyl, and cyclobutyl. The term C₁₋₆alkyl having 1 to 6 carbon atoms and may

be, but is not limited to, methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *i*-butyl, *s*-butyl, *t*-butyl, *n*-pentyl, *i*-pentyl, *t*-pentyl, *neo*-pentyl, *n*-hexyl, *i*-hexyl or cyclohexyl.

The term "alkenyl" refers to a straight or branched chain alkenyl group. The term
5 C₂₋₄alkenyl having 2 to 4 carbon atoms and one double bond, and may be, but is not limited to, vinyl, allyl, propenyl, *i*-propenyl, butenyl, *i*-butenyl, and crotyl.

The term "alkynyl" refers to a straight or branched chain alkynyl group. The term
C₂₋₄alkynyl having 2 to 4 carbon atoms and one triple bond, and may be, but is not limited
10 to, ethynyl, propargyl, butynyl, and *i*-butynyl.

The term "C₁₋₃alkoxy" includes both straight and branched chains. The term "C₁₋₃alkoxy"
having 1 to 3 carbon atoms and may be, but is not limited to, methoxy, ethoxy, *n*-propoxy,
or *i*-propoxy.

15 The term "halogen" refers to fluorine, chlorine, bromine and iodine.

The term "haloalkyl" refers to an alkyl group, defined as above, in which one or several of
the hydrogen substituents have been replaced by halogen substituents, in which the term
20 halogen is defined as above.

The term "aryl" refers to an optionally substituted monocyclic or bicyclic hydrocarbon ring
system containing at least one unsaturated aromatic ring. The "aryl" may be fused with a
C₅₋₇cycloalkyl ring to form a bicyclic hydrocarbon ring system. Examples and suitable
25 values of the term "aryl", but not limiting, are phenyl, naphthyl, indanyl or tetralinyl.

As used herein, "heteroaryl" refers to an aromatic heterocycle having at least one
heteroatom ring member such as sulfur, oxygen, or nitrogen. Heteroaryl groups include
monocyclic and polycyclic (e.g., having 2, 3 or 4 fused rings) systems. Examples of
30 heteroaryl groups include without limitation, pyridyl (i.e., pyridinyl), pyrimidinyl,
pyrazinyl, pyridazinyl, triazinyl, furyl (i.e. furanyl), quinolyl, isoquinolyl, thienyl,
imidazolyl, thiazolyl, indolyl, pyrrol, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl,

isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,4-thiadiazolyl, isothiazolyl, benzothienyl, purinyl, carbazolyl, fluorenonyl, benzimidazolyl, indolinyl, and the like. In some embodiments, the heteroaryl group has from 1 to about 20 carbon atoms, and in further embodiments from about 3 to about 20 carbon atoms. In some embodiments, the
5 heteroaryl group contains 3 to about 14, 4 to about 14, 3 to about 7, or 5 to 6 ring-forming atoms. In some embodiments, the heteroaryl or heteroaromatic group has 1 to about 4, 1 to about 3, or 1 to 2 heteroatoms. In some embodiments, the heteroaryl or heteroaromatic group has 1 heteroatom.

10 The term “4-, 5- or 6- membered heterocyclic ring containing one or more heteroatoms independently selected from N, O, or S” refers to a mono- or bicyclic- heterocyclic ring which may be saturated or partly saturated and which may optionally contain a carbonyl function and which may be, but is not limited to, azetidiny, imidazolidiny, imidazoliny, morpholiny, piperaziny, piperidiny, piperidony, pyrazolidiny, pyrazoliny, pyrrolidiny,
15 pyrroliny, 1-methyl-1,4-diazepane, tetrahydropyrany or thiomorpholiny. In the case where the heterocyclic ring contains a heteroatom selected from S or N, these atoms may optionally be in an oxidised form such as SO or SO₂.

The term “hydrochloride” includes monohydrochloride, dihydrochloride, trihydrochloride
20 and tetrahydrochloride salts.

A suitable pharmaceutically acceptable salt of the compound of the invention is, for example, an acid-addition salt, for example an inorganic or organic acid. In addition a suitable pharmaceutically acceptable salt of the compounds of the invention is an alkali
25 metal salt, an alkaline earth metal salt or a salt with an organic base that affords a physiologically-acceptable cation.

Some compounds of formula I may have chiral centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention encompasses all such
30 optical, diastereoisomers and geometric isomers.

The present invention relates to the use of compounds of formula I as hereinbefore defined as well as to the salts thereof. Salts for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of formula I.

5

It is to be understood that the present invention relates to any and all tautomeric forms of the compounds of formula I.

An object of the invention is to provide compounds of formula I for therapeutic use, especially compounds that are useful for the prevention and/or treatment of conditions associated with glycogen synthase kinase-3 (GSK3) in mammals including man. Particularly, compounds of formula I exhibiting a selective affinity for GSK-3.


10

Methods of Preparation

15

Another aspect of the present invention provides a process for preparing a compound of formula I, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, which process (wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R^b, R^c, R^d and R^e are, unless otherwise specified, as defined in formula I comprises of:


Process a) reacting an aminopyrimidine of formula (II):



20

(II)

with a compound of formula (III):



(III)

wherein Y is a displaceable group;

and thereafter if necessary:

- i) converting a compound of the formula **I** into another compound of the formula **I**;
- ii) removing any protecting groups;
- 5 iii) forming a pharmaceutically acceptable salt or in vivo hydrolysable ester.


Y is a displaceable group, suitable values for Y are for example, a halogeno or sulphonyloxy group, for example a chloro, bromo, iodo or trifluoromethanesulphonyloxy group. According to one embodiment of the present invention Y is bromo or iodo.

10

Specific reaction conditions for the reaction described in *Process a)* are as follows.

Aminopyrimidines of formula **(II)** and compounds of formula **(III)** may be reacted together under standard Buchwald-Hartwig conditions (see, for example, *J. Am. Chem. Soc.* **1996**, *118*, 7215; *J. Am. Chem. Soc.* **1997**, *119*, 8451; *J. Am. Chem. Soc.* **2003**, *125*,
 15 6653; *J. Org. Chem.* **1997**, *62*, 1568 and 6066), for example in the presence of palladium acetate, in a suitable solvent for example an aromatic solvent such as toluene, benzene or xylene, with a suitable base for example an inorganic base such as caesium carbonate or an organic base such as potassium-*t*-butoxide, in the presence of a suitable ligand such as 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl or 2-dicyclohexylphosphino-2',4',6'-triisopropyl-
 20 1,1'-biphenyl and at a temperature in the range of +25 to +80°C.

A synthesis of aminopyrimidines of formula **(II)** is described in *Scheme 1* (wherein R^x may be the same or different and is selected from C₁₋₆alkyl):




25

Scheme 1

Compounds of formula **(III)** are commercially available compounds, or they are known in the literature, or they can be prepared by standard processes known in the art.

Compounds of formula (IV), wherein R^6 has the general structure R^a-CH-R^b , wherein R^a and R^b are both alkyl, e.g. methyl and R^9 is fluoro may be prepared according to *Scheme*



Scheme 2

Compounds of formula (Va), (Vb) and (Vc) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

In one aspect of the invention, there is provided a process for preparing a compound of formula I which is the process described as *Process a)*.

It will be appreciated that certain of the various ring substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction

conditions for such procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group. Particular examples of modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.

It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Conventional protecting groups may be used in accordance with standard practice (for illustration see T.W. Greene, Protective Groups in Organic Synthesis, John Wiley and Sons, 1999). Thus, if reactants include groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.

A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or *t*-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a *t*-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is,

for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.

5 A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example
10 lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

A suitable protecting group for a carboxy group is, for example, an esterifying group, for
15 example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a *t*-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by
20 hydrogenation over a catalyst such as palladium-on-carbon.

The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.

One aspect of the present invention relates to intermediates for the end products of the
25 present invention. These intermediates are useful in the preparation of a compound of formula I as defined above. These intermediates are represented by, but not limited to, the following:

1-[4-Bromo-2-(methylsulfonyl)benzoyl]-4-methylpiperazine;
1-(4-Chloro-2-iodobenzoyl)-4-methylpiperazine;
30 5-Chloro-2-[(4-methylpiperazin-1-yl)carbonyl]benzonitrile;
1-(4-Chloro-2-methoxybenzoyl)-4-methylpiperazine;
2,2,2-Trifluoro-N-isopropyl-N-(5-methyl-isoxazol-4-yl)-acetamide;

5-Acetyl-2-trifluoromethyl-1-isopropyl-1H-imidazole;
(2E)-3-Dimethylamino-1-(2-trifluoromethyl-1-isopropyl-1H-imidazol-5-yl)prop-2-en-1-one;
(2Z)-3-Dimethylamino-2-fluoro-1-(2-trifluoromethyl-1-isopropyl-1H-imidazol-5-yl)prop-2-en-1-one; and
5 5-Fluoro-4-[2-trifluoromethyl-1-isopropyl-1H-imidazol-5-yl]pyrimidin-2-amine;
Methyl 3-[[5-fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino}benzoate.

10 General Methods

All solvents used were analytical grade and commercially available anhydrous solvents were routinely used for reactions. Reactions were typically run under an inert atmosphere of nitrogen or argon.

15 ^1H , ^{19}F and ^{13}C NMR spectra were recorded on a Varian Unity+ 400 NMR Spectrometer equipped with a 5mm BBO probehead with Z-gradients, or a Varian Gemini 300 NMR spectrometer equipped with a 5mm BBI probehead, or a Bruker Avance 400 NMR spectrometer equipped with a 60 μl dual inverse flow probehead with Z-gradients, or a Bruker DPX400 NMR spectrometer equipped with a 4-nucleus probehead equipped with
20 Z-gradients, or a Bruker Avance 600 NMR spectrometer equipped with a 5mm BBI probehead with Z-gradients. Unless specifically noted in the examples, spectra were recorded at 400 MHz for proton, 376 MHz for fluorine-19 and 100 MHz for carbon-13. The following reference signals were used: the middle line of DMSO- d_6 δ 2.50 (^1H), δ 39.51 (^{13}C); the middle line of CD_3OD δ 3.31 (^1H) or δ 49.15 (^{13}C); CDCl_3 δ 7.26 (^1H) and
25 the middle line of CDCl_3 δ 77.16 (^{13}C) (unless otherwise indicated).

Mass spectra were recorded on a Waters LCMS consisting of an Alliance 2795 (LC), Waters PDA 2996 and a ZQ single quadrupole mass spectrometer. The mass spectrometer was equipped with an electrospray ion source (ESI) operated in a positive or negative ion
30 mode. The capillary voltage was 3 kV and cone voltage was 30 V. The mass spectrometer was scanned between m/z 100-700 with a scan time of 0.3s. Separations were performed on either Waters X-Terra MS C8 (3.5 μm , 50 or 100 mm x 2.1 mm i.d.) or an ACE 3 AQ (100

mm x 2.1 mm i.d.) obtained from ScantecLab. Flow rates were regulated to 1.0 or 0.3 mL/min, respectively. The column temperature was set to 40 °C. A linear gradient was applied using a neutral or acidic mobile phase system, starting at 100% A (A: 95:5 10 mM NH₄OAc:MeCN, or 95:5 8 mM HCOOH:MeCN) ending at 100% B (MeCN).

5 Alternatively, mass spectra were recorded on a Waters LCMS consisting of an Alliance 2690 Separations Module, Waters 2487 Dual 1 Absorbance Detector (220 and 254 nm) and a Waters ZQ single quadrupole mass spectrometer. The mass spectrometer was equipped with an electrospray ion source (ESI) operated in a positive or negative ion mode. The capillary voltage was 3 kV and cone voltage was 30 V. The mass spectrometer was
10 scanned between *m/z* 97-800 with a scan time of 0.3 or 0.8 s. Separations were performed on a Chromolith Performance RP-18e (100 x 4.6 mm). A linear gradient was applied starting at 95% A (A: 0.1% HCOOH (aq.)) ending at 100% B (MeCN) in 5 minutes. Flow rate: 2.0 mL/min.

15 Microwave heating was performed in a single-mode microwave cavity producing continuous irradiation at 2450 MHz.

HPLC analyses were performed on an Agilent HP1000 system consisting of G1379A Micro Vacuum Degasser, G1312A Binary Pump, G1367A Well plate auto-sampler,
20 G1316A Thermostatted Column Compartment and G1315B Diode Array Detector. Column: X-Terra MS, Waters, 3.0 x 100 mm, 3.5 µm. The column temperature was set to 40 °C and the flow rate to 1.0 ml/min. The Diode Array Detector was scanned from 210-300 nm, step and peak width were set to 2 nm and 0.05 min, respectively. A linear gradient was applied, starting at 100 % A (A: 95:5 10 mM NH₄OAc:MeCN) and ending at 100% B
25 (B: MeCN), in 4 min.

Alternatively, HPLC analyses were performed on a Gynkotech P580 HPG consisting of gradient pump with a Gynkotech UVD 170S UV-vis.-detector equipped with a Chromolith Performance RP column (C18, 100 mm x 4.6 mm). The column temperature was set to +25
30 °C. A linear gradient was applied using MeCN/0.1 trifluoroacetic acid in MilliQ water, run from 10% to 100% MeCN in 5 minutes. Flow rate: 3 ml/min.

A typical workup procedure after a reaction consisted of extraction of the product with a solvent such as ethyl acetate, washing with water followed by drying of the organic phase over MgSO_4 or Na_2SO_4 , filtration and concentration of the solution *in vacuo*.

5 Thin layer chromatography (TLC) was performed on Merck TLC-plates (Silica gel 60 F₂₅₄) and UV visualized the spots. Flash chromatography was performed on a Combi Flash[®] Companion[™] using RediSep[™] normal-phase flash columns. Typical solvents used for flash chromatography were mixtures of chloroform/methanol, dichloromethane/methanol, heptane/ethyl acetate, chloroform/methanol/ammonia (aq.) and
10 dichloromethane/methanol/ NH_3 (aq.). SCX ion exchange columns were performed on Isolute[®] columns. Chromatography through ion exchange columns were typically performed in solvents such a methanol.

Preparative chromatography was run on a Waters autopurification HPLC with a diode
15 array detector. Column: XTerra MS C8, 19 x 300 mm, 10 μm . Narrow gradients with MeCN/(95:5 0.1M NH_4OAc :MeCN) were used at a flow rate of 20 ml/min. Alternatively, purification was achieved on a semi preparative Shimadzu LC-8A HPLC with a Shimadzu SPD-10A UV-vis.-detector equipped with a Waters Symmetry[®] column (C18, 5 μm , 100 mm x 19 mm). Narrow gradients with MeCN/0.1% trifluoroacetic acid in MilliQ Water
20 were used at a flow rate of 10 ml/min.

The formation of hydrochloride salts of the final products were typically performed in solvents or solvents mixtures such as diethyl ether, tetrahydrofuran, dichloromethane/toluene, dichloromethane/methanol, followed by addition of 1M
25 hydrogen chloride in diethyl ether.

The following abbreviations have been used:

aq.	aqueous;
BINAP	2,2'-bis(diphenylphosphino)-1,1'-binaphthyl
30 CHCl_3 .	chloroform
CDCl_3	deuterated chloroform
CD_3OD	deuterated methanol

	CH ₂ Cl ₂	dichloromethane
	Cs ₂ CO ₃	caesium carbonate
	DMF	<i>N,N</i> -dimethylformamide;
	DMFDMA	dimethylformamide dimethylacetal;
5	DMSO	dimethyl sulphoxide;
	dppf	1,1'-bis(diphenylphosphino)ferrocene;
	EDC	1-ethyl-3-(3-dimethylaminopropyl)carbodiimide;
	EDTA	ethylenediaminetetraacetic acid;
	ether	diethyl ether;
10	EtOAc	ethyl acetate;
	EtOH	ethanol
	H ₂	hydrogen gas
	HCOOH	acetic acid
	HCl	hydrochloride
15	HOAc	acetic acid
	HOBt	1-hydroxybenzotriazole;
	(i-Pr) ₂ NEt	<i>N,N</i> -diisopropylethylamine;
	MeCN	acetonitrile;
	MeOH	methanol;
20	Me ₃ SnCl	trimethyltin chloride;
	MgSO ₄	magnesium sulphate;
	NaCl	sodium chloride;
	NaBH ₃ CN	sodium cyanoborohydride;
	NaHCO ₃	sodium bicarbonate;
25	NaOMe	sodium methoxide;
	Na ₂ SO ₄	sodium sulphate;
	n-BuOH	n-butanol;
	NH ₃	ammonia;
	NH ₄ OAc	ammonium acetate;
30	NH ₄ OH	ammonium hydroxide;
	Pd/C	palladium on carbon;
	Pd(PPh ₃) ₂ Cl ₂	bis(triphenylphosphine)palladium dichloride;

Pd(<i>t</i> -Bu ₃ P) ₂	bis(tri- <i>tert</i> -butylphosphine)palladium;
Pd ₂ (dba) ₃	tris(dibenzylideneacetone)dipalladium;
Pd(OAc) ₂	palladium diacetate;
r.t. or RT	room temperature;
5 Selectfluor	<i>N</i> -fluoro- <i>N'</i> -chloromethyl-triethylenediamine-bis(tetrafluoroborate);
<i>t</i> -BuLi	tert-butyllithium
TEA	triethylamine;
THF	tetrahydrofuran;
X-Phos	2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl.

10

Starting materials used were either available from commercial sources or prepared according to literature procedures and had experimental data in accordance with those reported. The following is an example of a starting material that was prepared:

15

(4-Bromophenyl)(pyridin-2-yl)methanone: Bruce, R.B. et al., *J. Med. Chem.* **1968**, 5, 1031-1034.


20

Compounds have been named either using ACD/Name, version 8.08, software from Advanced Chemistry Development, Inc. (ACD/Labs), Toronto ON, Canada, www.acdlabs.com, 2004 or using Openeye lexichem version 1.4 (Copyright © 1997-2006 OpenEye Scientific Software, Santa Fe, New Mexico) to generate the IUPAC name.


25

In the following general methods A to C, the groups R¹, R² and R³ are used independently to indicate the diversity of substitution within each structure. The identity of R¹, R² and R³ will be clear to a person skilled in the art based on the starting materials and intermediates for each specific example. For instance in Example 15, which refers to General method C, C1 is 5-fluoro-4-[2-trifluoromethyl-1-isopropyl-1*H*-imidazol-5-yl]pyrimidin-2-amine such that R¹ is -CF₃ and C2 is 4-bromophenylsulphonylmethane such that R² is -sulphonylmethane *para*- to the halogen.

30


General Method A

(*i*-Pr)₂NEt (2.1 equiv.), HOBt (1.05 equiv.), EDC hydrochloride (1.05 equiv.) and the amine A2 (1.05 equiv.) were added to a stirred solution of the benzoic acid A1 (1.0 equiv.) in anhydrous DMF at r.t.. After 15 h, the reaction mixture was poured onto water and extracted with EtOAc. The organic layer was washed with water and brine, dried (Na₂SO₄), filtered and evaporated *in vacuo* to afford the crude product, which was used in the next step without further purification.

General Method B

B1 (1.0 equiv.), **B2** (0.85-1.24 equiv.) and sodium tert-butoxide (1.34-1.46 equiv.) were mixed in 1,4-dioxane and the mixture was flushed with argon for 5-10 minutes before Pd(OAc)₂ (0.04-0.082 equiv.) and Pd(*t*-Bu₃P)₂ (0.044-0.06 equiv.) were added. The mixture was flushed with argon then heated in a sealed tube at +110°C-+120 °C until the reaction was complete (as monitored by TLC or LC-MS). If the reaction was not complete after 24 h more Pd(OAc)₂, Pd(*t*-Bu₃P)₂ and sodium tert-butoxide were added. The solvent was removed *in vacuo* and the residue was partitioned between CH₂Cl₂ and water. After extraction the organic layer was dried (Na₂SO₄), filtered and evaporated. The crude of the free base was purified using preparative HPLC. MeCN was evaporated *in vacuo* and the aqueous phase was extracted with CH₂Cl₂. The organic phase was washed with water at pH 9 (diluted NaHCO₃ solution), dried (Na₂SO₄), filtered and evaporated. The residue was dissolved in CH₂Cl₂ and the HCl-adduct of the product was precipitated from the solution by addition of 0.1M HCl in ether (2-3 equiv. HCl). The solvent was evaporated and the residue was dissolved in water and freeze dried.

General Method C



C1 (1.01-1.27 equiv.), **C2** (1.0 equiv.) and Cs_2CO_3 (1.66-2.02 equiv.) were mixed in anhydrous 1,4-dioxane and the mixture was flushed with argon for 5 minutes before $\text{Pd}_2(\text{dba})_3$ (0.05-0.08 equiv.) and X-Phos (0.10-0.16 equiv.) were added. The mixture was flushed with argon, then heated in a sealed tube at +90-100 °C until the reaction was complete. The solvent was removed *in vacuo* and the residue was taken up in CH_2Cl_2 and washed with diluted NaHCO_3 (aq.). The organic layer was dried (Na_2SO_4), filtered and evaporated. The crude of the base product was purified using preparative HPLC.


EXAMPLES

Below follows a number of non-limiting examples of compounds of the invention.

Example 1

(4-{[5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-yl]amino}phenyl)(phenyl)methanone hydrochloride

*Example 1(a) (2Z)-3-(Dimethylamino)-2-fluoro-1-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)prop-2-en-1-one*




Selectfluor (1.32 g, 3.72 mmol) was added to a cooled (-70 °C) solution of (2*E*)-3-(dimethylamino)-1-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)prop-2-en-1-one (described in WO 03/076436) (0.634 g, 2.86 mmol) in MeOH (10 mL) under nitrogen atmosphere. The reaction mixture was stirred at -70 °C for 25 minutes, then stirred at r.t. for 3 h. Ammonia

(32% aq., 3 mL) was added and the two layers were separated. After extraction with CH₂Cl₂, the combined organic phases were washed with saturated NaCl (aq.), dried (Na₂SO₄), filtered and evaporated *in vacuo*. The crude product was purified by flash chromatography (CH₂Cl₂/MeOH gradient; 0 to 10 % MeOH) to give the title compound (0.311 g, 45%).

¹H NMR (CDCl₃) δ ppm 7.34 (s, 1 H), 6.85 (d, *J*=27.6 Hz, 1 H), 5.05-4.94 (m, 1 H), 3.11 (s, 3 H), 3.11 (s, 3 H), 2.52 (s, 3 H), 1.53 (d, *J*=7.0 Hz, 6 H); MS (ESI) *m/z* 240 (M+1).


Example 1(b) 5-Fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-amine



A reaction mixture of (2*Z*)-3-(dimethylamino)-2-fluoro-1-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)prop-2-en-1-one (0.170 g, 0.71 mmol, obtained from Example 1(a)), guanidine hydrochloride (0.170 g, 1.78 mmol) and sodium methoxide (0.154 g, 2.84 mmol) in 1-butanol was heated in a microwave reactor for 10 minutes at +140 °C under argon or nitrogen atmosphere. The mixture was filtered and the filtered mixture was rinsed with CH₂Cl₂. The solvent was evaporated *in vacuo* and the crude product was purified using flash column chromatography (EtOAc/MeOH-gradient; 0-10% MeOH) to give the title compound (0.119 g, 71%).

¹H NMR (CDCl₃) δ ppm 8.16 (d, *J*=3.3 Hz, 1 H), 7.55 (d, *J*=3.8 Hz, 1 H), 5.49-5.34 (m, 1 H), 4.86 (br s, 2 H), 2.60 (s, 3 H), 1.57 (d, *J*=7.1 Hz, 6 H); MS (ESI) *m/z* 236 (M+1).

Example 1(c) (4-{[5-Fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino}phenyl)(phenyl)methanone hydrochloride




The title compound was prepared in accordance with the general method B using 5-fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-amine (50 mg, 0.21 mmol, obtained from Example 1(b)), 4-bromobenzophenone (53.4 mg, 0.20 mmol), sodium tert-butoxide (27.4 mg, 0.28 mmol), Pd(OAc)₂ (3.3 mg, 0.015 mmol) and Pd(*t*-Bu₃P)₂ (5.1 mg, 0.010 mmol) to give the title compound (28 mg, 32%).

¹H NMR (DMSO-*d*₆) δ ppm 10.35 (s, 1 H), 8.87 (d, *J*=2.0 Hz, 1 H), 8.05 (s, 1 H), 7.88 (d, *J*=8.8 Hz, 2 H), 7.75 (d, *J*=8.6 Hz, 2 H), 7.72-7.62 (m, 3 H), 7.55 (t, *J*=7.5 Hz, 2 H), 5.36-5.20 (m, 1 H), 2.77 (s, 3 H), 1.51 (d, *J*=6.8 Hz, 6 H); MS (ESI) *m/z* 416 (M+1).

Example 2

(4-{[5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-yl]amino}phenyl)(pyridin-2-yl)methanone hydrochloride




The title compound was prepared in accordance with the general method B but using a 70 h reaction time. Starting from 5-fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-amine (obtained from Example 1(b)) (47.7 mg, 0.203 mmol), (4-bromophenyl)(pyridin-2-yl)methanone (Bruce, R.B., et al., *J. Med. Chem.*, **1968**, 5, 1031-1034) (53.8 mg, 0.205 mmol), sodium tert-butoxide (27.8 mg, 0.289 mmol), Pd(OAc)₂ (2.5 mg, 0.011 mmol) and Pd(*t*-Bu₃P)₂ (6.5 mg, 0.013 mmol), the title compound (17 mg, 17%) was obtained as a solid.

¹H NMR (DMSO-*d*₆, 600 MHz) δ ppm 10.41 (s, 1 H), 8.90 (d, *J*=1.4 Hz, 1 H), 8.71 (d, *J*=4.6 Hz, 1 H), 8.13 (d, *J*=1.4 Hz, 1 H), 8.08-8.03 (m, 1 H), 8.00 (d, *J*=8.8 Hz, 2 H), 7.93 (d, *J*=7.7 Hz, 1 H), 7.86 (d, *J*=8.8 Hz, 1 H), 7.68-7.63 (m, 1 H), 5.31-5.21 (m, 1 H), 2.81 (s, 3 H), 1.52 (d, *J*=6.8 Hz, 6 H); MS (ESI) *m/z* 417 (M+1).

Example 3

(4-{[5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-yl]amino}phenyl)(pyridin-3-yl)methanone hydrochloride




The title compound was prepared in accordance with the general method B using 5-fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-amine (obtained from Example 1(b)) (59 mg, 0.25 mmol), (4-bromophenyl)(pyridin-3-yl)methanone (Bäckvall, J.-E., et al., *J. Org. Chem.*, **1981**, 46, 3479-3483) (56 mg, 0.213 mmol), sodium tert-butoxide (33.8 mg, 0.35 mmol), Pd(OAc)₂ (2.9 mg, 0.013 mmol) and Pd(*t*-Bu₃P)₂ (6.4 mg, 0.012 mmol) to give the title compound (35 mg, 34%) as a solid.

¹H NMR (DMSO-*d*₆) δ ppm 10.45 (s, 1 H), 8.91 (d, *J*=2.0 Hz, 1 H), 8.89 (d, *J*=1.3 Hz, 1 H), 8.85 (d, *J*=1.3 Hz, 1 H), 8.21-8.15 (m, 1 H), 8.13 (d, *J*=1.8 Hz, 1 H), 7.91 (d, *J*=8.8 Hz, 2 H), 7.79 (d, *J*=8.8 Hz, 2 H), 7.67 (dd, *J*=7.7, 5.1 Hz, 1 H), 5.32-5.18 (m, 1 H), 2.81 (s, 3 H), 1.52 (d, *J*=7.0 Hz, 6 H); MS (ESI) *m/z* 417 (M+1).

Example 4

5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-*N*-{3-methyl-4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrimidin-2-amine hydrochloride




The title compound was prepared in accordance with the general method B using 5-fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-amine (obtained from Example 1(b)) (40 mg, 0.17 mmol), 1-[(4-bromo-2-methylphenyl)sulfonyl]-4-methylpiperazine (described in WO 2003004472) (56 mg, 0.168 mmol), sodium tert-butoxide (22.7 mg, 0.236 mmol), Pd(OAc)₂ (3.0 mg, 0.013 mmol) and Pd(*t*-Bu₃P)₂ (5.0 mg, 0.010 mmol) to give the title compound (36 mg, 38%) as a solid.

^1H NMR (D_2O) δ ppm 8.52 (d, $J=2.0$ Hz, 1 H), 7.82 (d, $J=2.0$ Hz, 1 H), 7.73 (d, $J=8.8$ Hz, 1 H), 7.55 (dd, $J=8.8, 2.0$ Hz, 1 H), 7.42 (d, $J=1.3$ Hz, 1 H), 5.43-5.29 (m, 1 H), 3.83 (d, $J=12.9$ Hz, 2 H), 3.59 (d, $J=11.9$ Hz, 2 H), 3.26-3.03 (m, 4 H), 2.92 (s, 3 H), 2.81 (s, 3 H), 2.47 (s, 3 H), 1.51 (d, $J=7.1$ Hz, 6 H); MS (ESI) m/z 488 ($M+1$).

5

Example 5

5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-*N*-{2-methyl-4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrimidin-2-amine hydrochloride




10 The title compound was prepared in accordance with the general method B using 5-fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-amine (obtained from Example 1(b)) (59 mg, 0.25 mmol), 1-[(4-bromo-3-methylphenyl)sulfonyl]-4-methylpiperazine (described in WO 2003004472) (46.4 mg, 0.139 mmol), sodium tert-butoxide (21.7 mg, 0.23 mmol), $\text{Pd}(\text{OAc})_2$ (2.1 mg, 0.009 mmol) and $\text{Pd}(t\text{-Bu}_3\text{P})_2$ (5.0 mg, 0.010 mmol) to
15 give the title compound (17 mg, 18%) as a solid.

^1H NMR (CD_3OD) δ ppm 8.60 (d, $J=2.3$ Hz, 1 H), 7.98-7.89 (m, 2 H), 7.73 (d, $J=1.8$ Hz, 1 H), 7.66 (dd, $J=8.3, 2.3$ Hz, 1 H), 5.49-5.35 (m, 1 H), 4.33-3.35 (m, 8 H), 2.90 (s, 3 H), 2.80 (s, 3 H), 2.41 (s, 3 H), 1.49 (d, $J=7.1$ Hz, 6 H); MS (ESI) m/z 488 ($M+1$).

20 Example 6

5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-*N*-[4-[(4-methylpiperazin-1-yl)sulfonyl]-2-(trifluoromethyl)phenyl]pyrimidin-2-amine hydrochloride


Example 6(a) 1-{{[4-Bromo-3-(trifluoromethyl)phenyl]sulfonyl}-4-methylpiperazine



Triethylamine (1.39 mL, 10.0 mmol) was added dropwise to a solution of *N*-methylpiperazine (1.0 g, 10.1 mmol) and 4-bromo-3-(trifluoromethyl)benzenesulphonyl chloride (3.23 g, 10.0 mmol) in CH₂Cl₂ (50 mL). The resulting mixture was stirred at r.t. for 30 minutes. Saturated NaHCO₃ (aq., 30 mL) was added. The solution was extracted with CH₂Cl₂ and the organic layers were dried (MgSO₄), filtered and evaporated *in vacuo* to give the title compound (3.62 g, 94%) as a solid. This crude product was used in the next step without further purification.

¹H NMR (CDCl₃) δ ppm 8.01 (d, *J*=2.0 Hz, 1 H), 7.89 (d, *J*=8.3 Hz, 1 H), 7.74 (dd, *J*=8.3, 2.0 Hz, 1 H), 3.12 (s, 4 H), 2.57 (s, 4 H), 2.33 (s, 3 H); MS (ESI) *m/z* 387, 389 (*M*+1).

Example 6(b) 5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-*N*-[4-[(4-methylpiperazin-1-yl)sulfonyl]-2-(trifluoromethyl)phenyl]pyrimidin-2-amine hydrochloride




The title compound was prepared in accordance with the general procedure B but with the following modifications. After heating at +120 °C for 95 minutes, Pd(OAc)₂ (2 mg), Pd(*t*-Bu₃P)₂ (4.5 mg) and sodium tert-butoxide (15 mg) were added. Starting from 5-fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-amine (obtained from Example 1(b)) (47 mg, 0.20 mmol), 1-{{[4-bromo-3-(trifluoromethyl)phenyl]sulfonyl}-4-methylpiperazine (77 mg, 0.199 mmol, obtained from Example 6(a)), sodium tert-butoxide (26.6 mg, 0.277 mmol), Pd(OAc)₂ (2.0 mg, 0.009 mmol) and Pd(*t*-Bu₃P)₂ (5.1 mg, 0.010 mmol), the title compound (38 mg, 35%) was obtained as a solid.

^1H NMR (D_2O) δ ppm 8.51 (d, $J=2.3$ Hz, 1 H), 8.21 (s, 1 H), 8.13-8.04 (m, 2 H) 7.70 (d, $J=2.0$ Hz, 1 H), 5.22-5.09 (m, 1 H), 3.77-2.99 (m, 8 H), 2.82 (s, 3 H), 2.68 (s, 3 H), 1.37 (d, $J=6.8$ Hz, 6 H); MS (ESI) m/z 542 ($M+1$).

5 Example 7

5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-*N*-[4-[(4-methylpiperazin-1-yl)sulfonyl]-3-(trifluoromethoxy)phenyl]pyrimidin-2-amine hydrochloride




The title compound was prepared in accordance with the general method B using 5-fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-amine (obtained from Example 1(b)) (38.5 mg, 0.164 mmol), 1-[[4-bromo-2-(trifluoromethoxy)phenyl]sulfonyl]-4-methylpiperazine (described in WO 2003004472) (86 mg, 0.203 mmol), sodium tert-butoxide (22 mg, 0.229 mmol), $\text{Pd}(\text{OAc})_2$ (3.0 mg, 0.013 mmol) and $\text{Pd}(t\text{-Bu}_3\text{P})_2$ (4.0 mg, 0.008 mmol) to give the title compound (16 mg, 16%) as a solid.

^1H NMR (D_2O) δ ppm 8.58 (d, $J=1.8$ Hz, 1 H), 7.87 (br s, 1 H), 7.82 (d, $J=8.8$ Hz, 1 H), 7.78 (d, $J=1.5$ Hz, 1 H), 7.59 (dd, $J=8.8, 2.0$ Hz, 1 H), 5.31-5.17 (m, 1 H), 4.32-2.98 (m, 8 H), 2.91 (s, 3 H), 2.79 (s, 3 H), 1.51 (d, $J=7.1$ Hz, 6 H); MS (ESI) m/z 558 ($M+1$).

Example 8

5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-*N*-[4-[(4-methylpiperazin-1-yl)carbonyl]-3-(methylsulfonyl)phenyl]pyrimidin-2-amine hydrochloride

Example 8(a) 1-[4-Bromo-2-(methylsulfonyl)benzoyl]-4-methylpiperazine




Thionyl chloride (5 mL) was added to 4-bromo-2-(methylsulfonyl)benzoic acid (0.50 g, 1.67 mmol). After addition of 1 drop of anhydrous DMF, the reaction mixture was refluxed for 30 minutes under an atmosphere of nitrogen. The solvent was evaporated *in vacuo* and the residue was dissolved in CH₂Cl₂ (until a clear solution was obtained). *N*-

Methylpiperazine (0.195 mL, 1.75 mmol) was added dropwise followed by addition of triethylamine (0.243 mL, 1.75 mmol). The reaction mixture was stirred at r.t. for 15 minutes before it was diluted with CH₂Cl₂, washed with saturated NaHCO₃ (aq.), water, dried (Na₂SO₄), filtered and concentrated *in vacuo* to give the title compound in quantitative yield. The isolated material was used in the next step without further purification.

¹H NMR (DMSO-*d*₆, Signals corresponding to 3 protons were overlapping with the solvents) δ ppm 8.06 (d, *J*=2.0 Hz, 1 H), 8.01 (dd, *J*=8.3, 2.0 Hz, 1 H), 7.46 (d, *J*=8.0 Hz, 1 H), 3.65-3.53 (m, 2 H), 3.19-3.00 (m, 2 H), 2.43-2.33 (m, 2 H), 2.33-2.21 (m, 2 H), 2.19 (s, 3 H); MS (ESI) *m/z* 361, 363 (*M*+1).

Example 8(b) 5-Fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-N-[4-[(4-methylpiperazin-1-yl)carbonyl]-3-(methylsulfonyl)phenyl]pyrimidin-2-amine hydrochloride



Anhydrous 1,4-dioxane (2 mL) was added to 5-fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-amine (obtained from Example 1(b)) (52 mg, 0.22 mmol), 1-[4-bromo-2-(methylsulfonyl)benzoyl]-4-methylpiperazine (Bruce, R.B., et al. *J. Med. Chem.*, **1968**, 5, 1031-1034) (71.0 mg, 0.197 mmol, obtained from Example 8(a)) and sodium tert-butoxide (30.9 mg, 0.32 mmol). The mixture was purged with argon and Pd(OAc)₂ (2 mg, 0.009 mmol), Pd(*t*-Bu₃P)₂ (6.1 mg, 0.012 mmol) were added followed by another argon purge. The mixture was heated in a sealed tube at 120 °C. After stirring overnight Pd(*t*-Bu₃P)₂ (12.4 mg, 0.024 mmol) was added and after another 24 h the following reagents were added; Cs₂CO₃ (107 mg, 0.33 mmol), X-Phos (11.3 mg, 0.024 mmol) and Pd₂(dba)₃ (11.1 mg, 0.012 mmol). The resulting mixture was heated in an oil bath for +90 °C for 20


h. The mixture was filtered through diatomaceous earth and washed with EtOAc. The organic phase was washed with water, dried (Na_2SO_4), filtered and evaporated *in vacuo*. The residue was purified by flash chromatography (MeCN/5% TEA in MeCN gradient; 0 to 5% TEA in MeCN). The product-containing fractions were pooled together and
5 evaporated *in vacuo*. The residue was dissolved in CH_2Cl_2 and the organic phase was washed with EDTA (aq.) at pH 1. The EDTA (aq.) phase was neutralized (pH 7) with NaHCO_3 (aq.) and the product was extracted with CH_2Cl_2 . The organic phase was dried (Na_2SO_4), filtered and evaporated *in vacuo*. The residue was dissolved in CH_2Cl_2 /ether (1:1, 10 mL) and the title compound precipitated by dropwise addition of 1M HCl in ether
10 (2.0 equiv.). The precipitate was collected by filtration, rinsed with CH_2Cl_2 , dissolved in water and freeze dried to give the title compound (96 mg, 74 %) as a solid.

^1H NMR ($\text{DMSO}-d_6$) δ ppm 11.47-11.25 (m, 1 H), 10.41 (s, 1 H), 8.90 (d, $J=1.5$ Hz, 1 H), 8.30 (s, 1 H), 8.21 (d, $J=8.5$ Hz, 1 H), 8.12 (s, 1 H), 7.52 (d, $J=8.0$ Hz, 1 H), 5.29-5.12 (m, 1 H), 4.64-4.48 (m, 1 H), 3.62-3.04 (m, 6 H), 2.84-2.71 (m, 7 H), 2.76 (br s, 4 H), 1.52 (d,
15 $J=7.0$ Hz, 6 H); MS (ESI) m/z 516 ($M+1$).

Example 9

5-[[5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-yl]amino}-2-[(4-methylpiperazin-1-yl)carbonyl]benzonitrile hydrochloride


Example 9(a) 1-(4-Chloro-2-iodobenzoyl)-4-methylpiperazine



The title compound was prepared in accordance with the general method of Example 8 (a) with the exception that the reaction mixture was stirred in thionyl chloride under reflux for
25 60 minutes, and the reaction with the amine was stirred at r.t. overnight. Using 4-chloro-2-iodobenzoic acid (0.523 g, 1.85 mmol) and after purification with flash chromatography (CHCl_3 /MeOH gradient; 0 to 5% MeOH), the title compound (0.415 g, 61%) was obtained as a solid.

¹H NMR (DMSO-*d*₆) δ ppm 7.97 (d, *J*=2.0 Hz, 1 H), 7.54 (dd, *J*=8.3, 2.0 Hz, 1 H), 7.26 (d, *J*=8.3 Hz, 1 H), 3.69-3.53(m, 2 H), 3.08 (t, *J*=5.0 Hz, 2 H), 2.38 (t, *J*=5.1 Hz, 2 H), 2.36-2.21 (m, 2 H), 2.19 (s, 3 H); MS (ESI) *m/z* 365 (M+1).


5 *Example 9(b) 5-Chloro-2-[(4-methylpiperazin-1-yl)carbonyl]benzonitrile*



1-(4-Chloro-2-iodobenzoyl)-4-methylpiperazine (400 mg, 1.70 mmol, obtained from Example 9(a)), zinc acetate (17.2 mg, 0.079 mmol), zinc cyanide (109 mg, 0.928 mmol), zinc dust (8.0 mg, 0.122 mmol), Pd₂(dba)₃ (44 mg, 0.048 mmol) and dppf (117 mg, 0.211 mmol) were mixed in anhydrous 1,4-dioxane (1.5 mL) and flushed with argon. The mixture was heated in a sealed tube at +90-+95 °C for 45 minutes. The reaction mixture was filtered through diatomaceous earth and rinsed with EtOAc. The organic phase was washed with saturated NaHCO₃ (aq.), dried (Na₂SO₄), filtered and evaporated *in vacuo*. The crude product was purified by flash chromatography (CH₂Cl₂/MeOH-gradient; 0 to 5% MeOH) to give the title compound (280 mg, 62%).

¹H NMR (DMSO-*d*₆) δ ppm 8.16 (d, *J*=2.0 Hz, 1 H), 7.87 (dd, *J*=8.3, 2.0 Hz, 1 H), 7.59 (d, *J*=8.3 Hz, 1 H), 3.71-3.59 (m, 2 H), 3.24-3.14 (m, 2 H), 2.43-2.32 (m, 2 H), 2.32-2.22 (m, 2 H), 2.19 (s, 3 H); MS (ESI) *m/z* 264 (M+1).

20 *Example 9(c) 5-{[5-Fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino}-2-[(4-methylpiperazin-1-yl)carbonyl]benzonitrile hydrochloride*




The title compound was prepared in accordance with the general method C using 5-fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-amine (obtained from Example 1(b)) (53 mg, 0.225 mmol), 5-chloro-2-[(4-methylpiperazin-1-yl)carbonyl]benzonitrile (55 mg, 0.209 mmol, obtained from Example 9(b)), Cs₂CO₃ (114 mg, 0.350 mmol), Pd₂(dba)₃

(11.6 mg, 0.013 mmol) and X-Phos (10.6 mg, 0.022 mmol) to give the title compound (70 mg, 58%) as a solid. The hydrochloride was prepared in accordance with the general method D.

¹H NMR (DMSO-*d*₆) δ ppm 11.79 (br s, 1 H), 10.54 (s, 1 H), 8.91 (d, *J*=1.76 Hz, 1 H), 8.29 (d, *J*=2.01 Hz, 1 H), 8.11 (d, *J*=1.83 Hz, 1 H), 8.02 (dd, *J*=8.53, 2.26 Hz, 1 H), 7.62 (d, *J*=8.53 Hz, 1 H), 5.26 (s, 1 H), 4.57 (br s, 1 H), 3.75-2.95 (m, 8 H), 2.82 (s, 3 H), 2.77 (s, 3 H), 1.52 (d, *J*=7.03 Hz, 6 H); MS (ESI) *m/z* 463 (*M*+1).

Example 10

***N*-{3-Chloro-4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}-5-fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-amine hydrochloride**




The title compound was prepared in accordance with the general method C using 5-fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-amine (obtained from Example 1(b)) (49.4 mg, 0.211 mmol), 1-(2,4-dichlorobenzoyl)-4-methylpiperazine (Prasad, R.N., et al., *J. Med. Chem.*, **1968**, 6, 1144-1150) (57 mg, 0.209 mmol), Cs₂CO₃ (113 mg, 0.347 mmol), Pd₂(dba)₃ (9.9 mg, 0.011 mmol) and X-Phos (10.5 mg, 0.022 mmol) to give the title compound (50 mg, 44%) as a yellow solid. The hydrochloride was prepared in accordance with the general method B.

¹H NMR (DMSO-*d*₆) δ ppm 11.78 (br s, 1 H), 10.31 (s, 1 H), 8.88 (d, *J*=1.8 Hz, 1 H), 8.12 (d, *J*=2.0 Hz, 1 H), 7.94 (br s, 1 H), 7.71 (dd, *J*=8.3, 2.0 Hz, 1 H), 7.38 (br s, 1 H), 5.30-5.17 (m, 1 H), 4.57 (d, *J*=13.1 Hz, 1 H), 4.20-2.89 (m, 8 H), 2.83 (s, 3 H), 2.76 (s, 3 H), 1.51 (d, *J*=7.1 Hz, 6 H); MS (ESI) *m/z* 472 (*M*+1).


Example 11

5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-*N*-{3-methoxy-4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}pyrimidin-2-amine hydrochloride

Example 11(a) 1-(4-Chloro-2-methoxybenzoyl)-4-methylpiperazine

The title compound was prepared in accordance with the general method of Example 8(a) using 4-chloro-2-methoxybenzoic acid (0.501 g, 2.68 mmol) to give the title compound in quantitative yield. This crude product was used in the next step without further purification

¹H NMR (DMSO-*d*₆) δ ppm 7.18 (d, *J*=8.0 Hz, 1 H), 7.17 (d, *J*=2.0 Hz, 1 H), 7.05 (dd, *J*=8.0, 1.8 Hz, 1 H), 3.81 (s, 3 H), 3.67-3.51 (m, 2 H), 3.14-3.04 (m, 2 H), 2.38-2.27 (m, 2 H), 2.27-2.19 (m, 2 H), 2.18 (s, 3 H).


Example 11(b) 5-Fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-N-{3-methoxy-4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}pyrimidin-2-amine hydrochloride

The title compound was prepared in accordance with the general method C using 5-fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-amine (obtained from Example 1(b)) (49.8 mg, 0.212 mmol), 1-(4-chloro-2-methoxybenzoyl)-4-methylpiperazine (45 mg, 0.167 mmol), Cs₂CO₃ (110 mg, 0.338 mmol), Pd₂(dba)₃ (9.3 mg, 0.010 mmol) and X-Phos (11.3 mg, 0.024 mmol). The hydrochloride was prepared in accordance with the general method D to give the title compound (60 mg, 53%) as a solid.

¹H NMR (DMSO-*d*₆) δ ppm 11.38 (br s, 1 H), 10.06 (s, 1 H), 8.85 (d, *J*=2.0 Hz, 1 H), 8.12 (d, *J*=1.8 Hz, 1 H), 7.49 (dd, *J*=8.3, 1.8 Hz, 1 H), 7.39 (s, 1 H), 7.20 (d, *J*=8.3 Hz, 1 H), 5.30-5.15 (m, 1 H), 4.58 (d, *J*=13.3 Hz, 1 H), 3.81 (s, 3 H), 3.57-3.13 (m, 6 H), 3.13-2.87 (m, 2 H), 2.82 (s, 3 H), 2.79 (br s, 3 H), 1.51 (d, *J*=7.0 Hz, 6 H); MS (ESI) *m/z* 468 (M +1).

Example 12

4-{[5-Fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino}phenyl(pyridin-4-yl)methanone hydrochloride




The title compound was prepared in accordance with the general method C, with the exception that the base of the product was purified by flash chromatography (EtOAc/4% MeOH in EtOAc gradient; 0 to 4% MeOH in EtOAc). The hydrochloride of the title compound was prepared in accordance with the general method D. Using 5-fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-amine (obtained from Example 1(b)) (42.6 mg, 0.181 mmol), (4-chlorophenyl)(pyridin-4-yl)methanone (Högberg, T., et al., *J. Med. Chem.*, **1981**, 24, 1499-1507) (34.6 mg, 0.159 mmol), Cs₂CO₃ (93.0 mg, 0.285 mmol), Pd₂(dba)₃ (11.6 mg, 0.013 mmol) and X-Phos (12.6 mg, 0.026 mmol), the title compound (26 mg, 34%) was obtained as a solid.

¹H NMR (DMSO-*d*₆) δ ppm 10.51 (s, 1 H), 8.91 (d, *J*=1.8 Hz, 1 H), 8.88 (d, *J*=4.8 Hz, 2 H), 8.13 (d, *J*=1.5 Hz, 1 H), 7.92 (d, *J*=8.8 Hz, 2 H), 7.83-7.72 (m, 4 H), 5.31-5.17 (m, 1 H), 2.82 (s, 3 H), 1.52 (d, *J*=7.0 Hz, 6 H); MS (ESI) *m/z* 417 (M+1).

Example 13

5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-*N*-{4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}pyrimidin-2-amine hydrochloride




5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-amine (obtained from Example 1(b)) (64 mg, 0.272 mmol), 1-(4-bromobenzoyl)-4-methylpiperazine (described in WO 2003004472) (92 mg, 0.325 mmol), BINAP (51 mg, 0.082 mmol) and sodium tert-

butoxide (31 mg, 0.323 mmol) were mixed in 1,4-dioxane (2.0 mL). The mixture was flushed with argon for 5 minutes, then Pd(OAc)₂ (9.1 mg, 0.045 mmol) was added followed by another purge with argon. The reaction mixture was heated in a sealed tube at +110 °C for 30 minutes in a microwave reactor. The solvent was evaporated *in vacuo* and the residue was partitioned between CH₂Cl₂ and diluted NaHCO₃ (aq.). The aqueous phase was extracted with CH₂Cl₂ and the combined organic phases were dried (Na₂SO₄), filtered and evaporated. The crude was purified using preparative HPLC. The hydrochloride was prepared in accordance with the general method D to give the title compound (43 mg, 36%) as a solid.

¹H NMR (D₂O) δ ppm 8.54 (d, *J*=2.0 Hz, 1 H), 7.79 (d, *J*=2.0 Hz, 1 H), 7.63 (d, *J*=8.8 Hz, 2 H), 7.48 (d, *J*=8.6 Hz, 2 H), 5.39-5.26 (m, 1 H), 4.29-3.83 (m, 2 H), 3.79-3.33 (m, 4 H), 3.32-3.09 (m, 2 H), 2.95 (s, 3 H), 2.79 (s, 3 H), 1.52 (d, *J*=6.8 Hz, 6 H); MS (ESI) *m/z* 437 (M +1).

Example 14

5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-*N*-(4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl)pyrimidin-2-amine hydrochloride




The title compound was prepared in accordance with the general method described in

Example 13 with the exception that the base of the product was dissolved in CH₂Cl₂/toluene (1:1) when preparing the hydrochloride salt. Using 5-fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-amine (obtained from Example 1(b)) (38.0 mg, 0.161 mmol), 1-[(4-bromophenyl)sulfonyl]-4-methylpiperazine (described in WO 2003004472) (78.0 mg, 0.244 mmol), BINAP (20.0 mg, 0.032 mmol), sodium tert-butoxide (20.0 mg, 0.208 mmol) and Pd(OAc)₂ (5.0 mg, 0.022 mmol) the title compound (27 mg, 31%) was obtained.

^1H NMR (DMSO- d_6) δ ppm 11.00 (br s, 1 H), 10.46 (s, 1 H), 8.89 (d, $J=1.8$ Hz, 1 H), 8.09 (d, $J=1.5$ Hz, 1 H), 7.97 (d, $J=8.8$ Hz, 2 H), 7.70 (d, $J=8.8$ Hz, 2 H), 5.31-5.17 (m, 1 H), 3.79-3.68 (m, $J=11.4$ Hz, 2 H), 3.42 (d, $J=11.1$ Hz, 2 H), 3.13 (s, 2 H), 2.79 (s, 3 H), 2.72 (s, 3 H), 2.71-2.59 (m, 2 H), 1.52 (d, $J=7.1$ Hz, 6 H); MS (ESI) m/z 474 (M+1).


5

Example 15**5-Fluoro-4-[1-isopropyl-2-(trifluoromethyl)-1*H*-imidazol-5-yl]-*N*-[4-(methylsulfonyl)phenyl]pyrimidin-2-amine hydrochloride**

10 The title compound was prepared in accordance with the general method C using 5-fluoro-4-[2-trifluoromethyl-1-isopropyl-1*H*-imidazol-5-yl]pyrimidin-2-amine (obtained from Example 15(e)) (50 mg, 0.173 mmol), 4-bromophenyl methyl sulfone (41 mg, 0.173 mmol), Cs_2CO_3 (114 mg, 0.350 mmol), $\text{Pd}_2(\text{dba})_3$ (6 mg, 0.006 mmol) and X-Phos (5.3 mg, 0.011 mmol) to give the freebase of the title compound (41 mg, 53%) as a solid. The
15 hydrochloride was prepared in accordance with the method described within general method B.

^1H NMR (400 MHz, DMSO- d_6) δ ppm 10.35 (s, 1 H) 8.85 (s, 1 H) 7.76 - 8.04 (m, 4 H) 7.54 (br. s., 1 H) 4.97 - 5.13 (m, 1 H) 3.89 (br. s., 3 H) 1.47 (d, $J=6.57$ Hz, 6 H). MS (ES) m/z 444 (M+1).

20

Example 15(a) 2,2,2-Trifluoro-*N*-isopropyl-*N*-(5-methyl-isoxazol-4-yl)-acetamide


5-Methyl-4-amino-isoxazole (Reiter, L.A., *J. Org. Chem.* **1987**, 52, 2714-2726) (0.68 g, 5.1 mmol) and acetic acid (0.61 g, 10.2 mmol) were dissolved in MeOH (20 mL). Acetone

(0.56 ml, 7.6 mmol) was added and the mixture was cooled to 0 – (–5) °C and stirred for 1 h. Sodium cyanoborohydride (0.32 g, 5.1 mmol) was added to the reaction mixture at –5 °C, causing weak exothermic and gas evolution. The cooling bath was removed and the mixture was stirred at r.t. for 1 h, followed by the addition of a second portion of sodium cyanoborohydride (0.1 g, 1.6 mmol). After stirring for 2 h at r.t., the mixture was filtered and the filtrate was concentrated *in vacuo*. The residue was dissolved in toluene and re-concentrated. The residue was dissolved in THF (10 mL) and trifluoro acetic anhydride (3.2 g, 15.3 mmol) was added. The resulting mixture was stirred overnight at r.t. then for 1 h at +50 °C. The volatiles were removed *in vacuo* and the residue was dissolved in toluene and concentrated *in vacuo* to give the title compound (0.84 g, 77 %) as a solid.

¹H NMR (400 MHz, CDCl₃) δ ppm 8.11 (s, 1 H) 4.82 - 5.03 (m, 1 H) 2.39 (s, 3 H) 1.16 (d, *J*=6.82 Hz, 3 H) 1.08 (d, *J*=6.82 Hz, 3 H); MS (CI) *m/z* 236 (M⁺).


Example 15(b)

5-Acetyl-2-trifluoromethyl-1-isopropyl-1H-imidazole



2,2,2-Trifluoro-N-isopropyl-N-(5-methyl-isoxazol-4-yl)-acetamide (2 g, 8.5 mmol, obtained from Example 15(a)) was dissolved in EtOH (30 ml), and the mixture was hydrogenated over Pd/C (10%, wet paste, 0.10 g) at 3 bar. The reaction mixture was stirred at +50 °C for 3 h. An additional amount of Pd/C (10%, wet paste, 0.15 g) was added and the mixture was continued stirring at +50 °C for 3 h. Sodium methoxide (1.38 g, 26 mmol) was added and the resulting mixture was heated at reflux for 30 h. Ammonium chloride was added to quench the reaction. The mixture was filtered through diatomaceous earth and the filtrate was evaporated *in vacuo*. The residue was diluted with saturated sodium bicarbonate (aq.) and extracted with EtOAc, then with CHCl₃. The combined organic layers were dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by flash chromatography (CH₂Cl₂/MeOH, 20:1) to give the title compound (1.33 g, 71%). ¹H NMR (400 MHz, CDCl₃) δ ppm 7.84 (s, 1 H) 4.96 (s, 1 H) 2.56 (s, 3 H) 1.58 (d, *J*=6.82 Hz, 6 H); MS (CI) *m/z* 220 (M⁺).


Example 15(c) (2E)-3-Dimethylamino-1-(2-trifluoromethyl-1-isopropyl-1H-imidazol-5-yl)prop-2-en-1-one



5 5-Acetyl-2-trifluoromethyl-1-isopropyl-1H-imidazole (1.33 g, 6 mmol, obtained from Example 15(b)) was dissolved in DMFDMA/DMF (1:1, 100 mL) and the mixture was stirred under reflux overnight. After cooling to r.t. the mixture was extracted with CH₂Cl₂. The organic phase was dried (Na₂SO₄), filtered and concentrated *in vacuo*. The crude product was purified by flash chromatography (CH₂Cl₂/MeOH 25:1) to give the title
10 compound (1.6 g, 73%).


¹H NMR (400 MHz, CDCl₃) δ ppm 7.68 (d, *J*=12.38 Hz, 1 H) 7.47 (s, 1 H) 5.49 (d, *J*=12.38 Hz, 1 H) 4.88 - 5.03 (m, 1 H) 3.15 (br. s., 3 H) 2.92 (br. s., 3 H) 1.62 (d, *J*=6.82 Hz, 6 H); MS (CI) *m/z* 275 (M⁺).

15 Example 15(d) (2Z)-3-Dimethylamino-2-fluoro-1-(2-trifluoromethyl-1-isopropyl-1H-imidazol-5-yl)prop-2-en-1-one



The title compound was prepared in accordance with the method described in Example 1 (a), with the exception that the product did not need any purification and it was used crude
20 in the next step. Using (2E)-3-dimethylamino-1-(2-trifluoromethyl-1-isopropyl-1H-imidazol-5-yl)prop-2-en-1-one (1.6 g, 5.8 mmol, obtained from Example 15(c)) the title compound was obtained (0.42 g, 25%). MS (CI) *m/z* 293 (M⁺).

Example 15(e) 5-Fluoro-4-[2-trifluoromethyl-1-isopropyl-1H-imidazol-5-yl]pyrimidin-2-amine




The title compound was prepared in accordance with the method described in Example 1 (b) with the exception that guanidine carbonate was used. Using (2*Z*)-3-dimethylamino-2-fluoro-1-(2-trifluoromethyl-1-isopropyl-1*H*-imidazol-5-yl)prop-2-en-one (1.47 g, 5.22 mmol, obtained 15(d)) and guanidine carbonate (2.35 g, 13.06 mmol) the title compound (0.53 g, 33%) was obtained as a solid after purification by flash chromatography (CH₂Cl₂/MeOH 20:1).

¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 8.28 (d, *J*=2.53 Hz, 1 H) 7.53 (d, *J*=3.03 Hz, 1 H) 5.04 - 5.14 (m, 1 H) 5.02 (br. s., 2 H) 1.61 (d, *J*=7.07 Hz, 6 H); MS (ES) *m/z* 290 (M+1).

Example 16

[5-Fluoro-4-(3-isopropyl-2-trifluoromethyl-3H-imidazol-4-yl)-pyrimidin-2-yl]-[4-(4-methyl-piperazine-1-sulfonyl)-phenyl]-amine hydrochloride




The title compound was prepared in accordance with the general method C using 5-fluoro-4-[2-trifluoromethyl-1-isopropyl-1*H*-imidazol-5-yl]pyrimidin-2-amine (obtained from Example 15(e)) (50 mg, 0.173 mmol), 1-[(4-bromophenyl)sulfonyl]-4-methylpiperazine (56 mg, 0.173 mmol), Cs₂CO₃ (114 mg, 0.350 mmol), Pd₂(dba)₃ (6 mg, 0.006 mmol) and X-Phos (5.3 mg, 0.011 mmol) to give the freebase of the title compound (10 mg, 3%) as a

solid. The hydrochloride was prepared in accordance with the method described within general method B.

¹H NMR (400 MHz, CD₃OD) δ ppm 8.65 (s, 1 H) 7.67 - 8.11 (m, 4 H) 7.53 (s, 1 H) 5.08 - 5.27 (m, 1 H) 3.82 - 4.04 (m, 2 H) 3.48 - 3.70 (m, 2 H) 3.12 - 3.28 (m, 2 H) 2.90 (s, 3 H) 2.61 - 2.81 (m, 2 H) 1.56 (d, *J*=5.30 Hz, 6 H); MS (ES) *m/z* 528 (M+1).

Example 17

{4-[5-Fluoro-4-(3-isopropyl-2-trifluoromethyl-3H-imidazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone hydrochloride




The title compound was prepared in accordance with the general method C using 5-fluoro-4-[2-trifluoromethyl-1-isopropyl-1*H*-imidazol-5-yl]pyrimidin-2-amine (obtained from Example 15(e)) (50 mg, 0.173 mmol), 1-(4-bromobenzoyl)-4-methylpiperazine (49 mg, 0.173 mmol), Cs₂CO₃ (114 mg, 0.350 mmol), Pd₂(dba)₃ (6 mg, 0.006 mmol) and X-Phos (5.3 mg, 0.011 mmol) to give the freebase of the title compound (25 mg, 29%) as a solid. The hydrochloride was prepared in accordance with the method described within general method B.

¹H NMR (400 MHz, CDCl₃) δ ppm 8.41 - 8.48 (m, 1 H) 7.62 (d, *J*=8.59 Hz, 2 H) 7.54 (d, *J*=3.03 Hz, 1 H) 7.42 (d, *J*=8.59 Hz, 2 H) 7.33 (s, 1 H) 5.07 - 5.22 (m, 1 H) 3.35 - 3.97 (m, 4 H) 2.36 - 2.52 (m, 4 H) 2.34 (s, 3 H) 1.56 (d, *J*=7.07 Hz, 6 H); MS (ES) *m/z* 490 (M-1).

Example 18


3-{{5-Fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl}amino}-N-(3-methoxypropyl)benzamide hydrochloride



Methyl 3-{{[5-fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino}benzoate (obtained from Example 18(a)) (40 mg, 0.11 mmol) and 3-methoxypropylamine (58 mg, 0.65 mmol) were mixed in toluene (4 mL) and an inert argon
 5 atmosphere was established. The sealed vial was cooled to r.t. and $\text{Al}(\text{CH}_3)_3$ (156 mg, 2.16 mmol) was added by a syringe. The reaction mixture was heated in an oil-bath at +90-100°C for 4 h, cooled to r.t., and added dropwise into ice-cold sat. NaHCO_3 (aq) under vigorous stirring. The product was extracted with CH_2Cl_2 and the organic layer was dried by treatment with Na_2SO_4 . The crude base of the product was purified using flash column
 10 chromatography (gradient from 100 % EtOAc to 5 % MeOH in EtOAc) and then the hydrochloride was prepared according to the method described within Example B to yield the title compound (8 mg, 16%).

^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 9.90 (s, 1 H) 8.78 (d, 1 H) 8.39 (t, 1 H) 8.07 (d, 1 H) 8.01 (t, 1 H) 7.78 (dd, 1 H) 7.49 - 7.42 (m, 1 H) 7.37 (t, 1 H) 5.33 - 5.19 (m, 1 H) 3.22
 15 (s, 3 H) 2.75 (s, 3 H) 1.79 - 1.68 (m, 2 H) 1.45 (s, 3 H) 1.43 (s, 3 H) some signals were partly obscured by the HDO signal; MS (ESI) m/z 427 (M+1).

Example 18(a) *Methyl 3-{{[5-fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino}benzoate*



5-Fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-amine (obtained from Example 1(b)) (99 mg, 0.42 mmol), methyl 3-bromobenzoate (97 mg, 0.45 mmol) and Cs_2CO_3 (230 mg, 0.71 mmol) were mixed in anhydrous 1,4-dioxane and the mixture was flushed with argon for 10 minutes before $\text{Pd}_2(\text{dba})_3$ (23 mg, 0.025 mmol) and X-Phos (24
 25 mg, 0.050 mmol) were added. The mixture was flushed with argon, then heated in a sealed

tube at +90-100 °C until the reaction was complete. The reaction mixture was diluted with CH₂Cl₂, filtered and evaporated. The residue was taken up in CH₂Cl₂ and the organic phase was washed with H₂O. Residual water was removed from the organic phase by treatment with Na₂SO₄. The crude of the base product was purified using preparative HPLC to give
5 the title compound (97 mg, 62%) as a solid.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 9.73 (s, 1 H) 8.57 (d, 1 H) 8.19 (t, 1 H) 8.04 - 7.95 (m, 1 H) 7.59 - 7.52 (m, 1 H) 7.43 (t, 1 H) 7.37 (d, 1 H) 5.44 - 5.31 (m, 1 H) 3.84 (s, 3 H) 2.51 (s, 3 H) 1.42 (d, 3 H) 1.40 (d, 3 H); MS (ESI) *m/z* 370 (M+1).

10 **Pharmaceutical compositions**

According to one aspect of the present invention there is provided a pharmaceutical composition comprising a compound of formula **I**, as a free base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, for use in the prevention and/or treatment of conditions associated with glycogen synthase kinase-3.

15 The composition may be in a form suitable for oral administration, for example as a tablet, for parenteral injection as a sterile solution or suspension. In general the above compositions may be prepared in a conventional manner using pharmaceutically carriers or diluents. Suitable daily doses of the compounds of formula **I** in the treatment of a mammal, including man, are approximately 0.01 to 250 mg/kg bodyweight at peroral administration
20 and about 0.001 to 250 mg/kg bodyweight at parenteral administration. The typical daily dose of the active ingredients varies within a wide range and will depend on various factors such as the relevant indication, the route of administration, the age, weight and sex of the patient and may be determined by a physician.

25 A compound of formula **I**, or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, can be used on its own but will usually be administered in the form of a pharmaceutical composition in which the formula **I** compound/salt/solvate (active ingredient) is in association with a pharmaceutically acceptable excipient, diluent or
30 carrier. Dependent on the mode of administration, the pharmaceutical composition may comprise from 0.05 to 99 %w (per cent by weight), for example from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.

An excipient, diluent or carrier includes water, aqueous polyethylene glycol, magnesium carbonate, magnesium stearate, talc, a sugar (such as lactose), pectin, dextrin, starch, tragacanth, microcrystalline cellulose, methyl cellulose, sodium carboxymethyl cellulose
5 or cocoa butter.

A composition of the invention can be in tablet or injectable form. The tablet may additionally comprise a disintegrant and/or may be coated (for example with an enteric coating or coated with a coating agent such as hydroxypropyl methylcellulose).

10 The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula I, or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, as hereinbefore defined, with a pharmaceutically acceptable excipient, diluent or carrier.

15 An example of a pharmaceutical composition of the invention is an injectable solution containing a compound of the invention, or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, as hereinbefore defined, and sterile water, and, if necessary, either sodium hydroxide or hydrochloric acid to bring the pH of the final composition to about
20 pH 5, and optionally a surfactant to aid dissolution.

Medical use

Surprisingly, it has been found that the compounds defined in the present invention, as a free base or a pharmaceutically acceptable salt thereof, are well suited for inhibiting
25 glycogen synthase kinase-3 (GSK3). Accordingly, the compounds of the present invention are expected to be useful in the prevention and/or treatment of conditions associated with glycogen synthase kinase-3 activity, i.e. the compounds may be used to produce an inhibitory effect of GSK3 in mammals, including man, in need of such prevention and/or treatment.

30 GSK3 is highly expressed in the central and peripheral nervous system and in other tissues. Thus, it is expected that compounds of the invention are well suited for the prevention

and/or treatment of conditions associated with glycogen synthase kinase-3 in the central and peripheral nervous system. In particular, the compounds of the invention are expected to be suitable for prevention and/or treatment of conditions associated with especially, dementia, Alzheimer's Disease, Parkinson's Disease, Frontotemporal dementia
5 Parkinson's Type, Parkinson dementia complex of Guam, HIV dementia, diseases with associated neurofibrillar tangle pathologies and dementia pugilistica.

Other conditions are selected from the group consisting of amyotrophic lateral sclerosis, corticobasal degeneration, Down syndrome, Huntington's Disease, postencephalic
10 parkinsonism, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, stroke, head trauma and other chronic neurodegenerative diseases, Bipolar Disease, affective disorders, depression, schizophrenia, cognitive disorders, hair loss and contraceptive medication.

Further conditions are selected from the group consisting of predemented states, Mild Cognitive Impairment, Age-Associated Memory Impairment, Age-Related Cognitive Decline, Cognitive Impairment No Dementia, mild cognitive decline, mild neurocognitive decline, Late-Life Forgetfulness, memory impairment and cognitive impairment, vascular dementia, dementia with Lewy bodies, Frontotemporal dementia and androgenetic alopecia
20 and Type I and Type II diabetes, diabetic neuropathy and diabetes related disorders.

One embodiment of the invention relates to the prevention and/or treatment of dementia and Alzheimer's Disease.

25 Another embodiment of the invention relates to the prevention and/or treatment of bone-related disorders.

The dose required for the therapeutic or preventive treatment of a particular disease will necessarily be varied depending on the host treated, the route of administration
30 and the severity of the illness being treated.

The present invention relates also to the use of a compound of formula I as defined hereinbefore, in the manufacture of a medicament for the prevention and/or treatment of conditions associated with glycogen synthase kinase-3.

5 In the context of the present specification, the term "therapy" also includes "prevention" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

10 The invention also provides for a method of treatment and/or prevention of conditions associated with glycogen synthase kinase-3 comprising administering to a mammal, including man in need of such treatment and/or prevention a therapeutically effective amount of a compound of formula I, as hereinbefore defined.

Non-medical use

15 In addition to their use in therapeutic medicine, the compounds of formula I as a free base or a pharmaceutically acceptable salt thereof, are also useful as pharmacological tools in the development and standardisation of *in vitro* and *in vivo* test systems for the evaluation of the effects of inhibitors of GSK3 related activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutics agents.

20 Pharmacology

Determination of ATP competition in Scintillation Proximity GSK3 β Assay.

GSK3 β scintillation proximity assay.

25 The competition experiments were carried out in duplicate with 10 different concentrations of the inhibitors in clear-bottom microtiter plates (Wallac, Finland). A biotinylated peptide substrate, Biotin-Ala-Ala-Glu-Glu-Leu-Asp-Ser-Arg-Ala-Gly-Ser(PO₃H₂)-Pro-Gln-Leu (AstraZeneca, Lund), was added at a final concentration of 1 μ M in an assay buffer containing 1 mU recombinant human GSK3 β (Dundee University, UK), 12 mM morpholinepropanesulfonic acid (MOPS), pH 7.0, 0.3 mM EDTA, 0.01% β -mercaptorethanol, 0.004 % Brij 35 (a natural detergent), 0.5 % glycerol and 0.5 μ g BSA/25
30 μ l. The reaction was initiated by the addition of 0.04 μ Ci [γ -³³P]ATP (Amersham, UK) and unlabelled ATP at a final concentration of 1 μ M and assay volume of 25 μ l. After

incubation for 20 minutes at room temperature, each reaction was terminated by the addition of 25 μ l stop solution containing 5 mM EDTA, 50 μ M ATP, 0.1 % Triton X-100 and 0.25 mg streptavidin coated Scintillation Proximity Assay (SPA) beads (Amersham, UK). After 6 hours the radioactivity was determined in a liquid scintillation counter (1450 MicroBeta Trilux, Wallac). The inhibition curves were analysed by non-linear regression using GraphPad Prism, USA. The K_m value of ATP for GSK3 β , used to calculate the inhibition constants (K_i) of the various compounds, was 20 μ M.

The following abbreviations have been used:

10	MOPS	Morpholinepropanesulfonic acid
	EDTA	Ethylenediaminetetraacetic acid
	BSA	Bovin Serum Albumin
	ATP	Adenosine Triphosphate
	SPA	Scintillation Proximity Assay
15	GSK3	Glycogen synthase kinase 3

Results


Typical K_i values for the compounds of the present invention are in the range of about 0.001 to about 10,000 nM. Other values for K_i are in the range of about 0.001 to about 1000 nM. Further values for K_i are in the range of about 0.001 nM to about 300 nM.

Table 1. Specimen results from assay.

Example no	K_i (nM)	n
2	1.3	4
5	24	4
11	25	3
13	3.8	3

CLAIMS

1. Use of a compound of formula I,



wherein

- 5 R^1 is selected from hydrogen, halo, CN, NO₂, C₁₋₃alkyl, C₁₋₃haloalkyl, OR^a, SO₂NR^bR^c, C(O)NR^bR^c, CH₂NR^bR^c, CH₂OR^h, SO₂Rⁱ and C(O)R^j;
- R^2 and R^4 are independently selected from hydrogen, halo, CN, NO₂, C₁₋₃alkyl, C₁₋₃haloalkyl, OR^a, SO₂NR^bR^c, C(O)NR^bR^c, CH₂NR^bR^c, CH₂OR^h, SO₂Rⁱ and C(O)R^j;
- R^3 and R^5 independently are selected from hydrogen, C₁₋₃alkyl, C₁₋₃haloalkyl and OR^a;
- 10 R^6 is selected from C₂₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, and C₂₋₄haloalkyl;
- R^7 is selected from C₁₋₃alkyl, CN, and C₁₋₃haloalkyl, said C₁₋₃alkyl or C₁₋₃haloalkyl optionally substituted with one or more OR^a;
- R^8 and R^9 are independently selected from hydrogen, CN and halo;
- R^a is hydrogen, C₁₋₃alkyl or C₁₋₃haloalkyl, said C₁₋₃alkyl or C₁₋₃haloalkyl optionally substituted with one or more C₁₋₃alkoxy;
- 15 R^b and R^c are independently selected from hydrogen, C₁₋₆alkyl or C₁₋₆haloalkyl, said C₁₋₆alkyl or C₁₋₆haloalkyl optionally substituted with one or more OR^a or NR^dR^e; or
- R^b and R^c may, together with the atom to which they are attached, form a 4-, 5- or 6-membered heterocyclic ring containing one or more heteroatoms selected from N, O or S,
- 20 wherein said heterocyclic ring is optionally substituted with one or more halo, C₁₋₃alkyl or C₁₋₃haloalkyl, said C₁₋₃alkyl or C₁₋₃haloalkyl optionally further substituted with one or more C₁₋₃alkoxy;
- R^d and R^e are independently selected from hydrogen, C₁₋₆alkyl or C₁₋₆haloalkyl, said C₁₋₆alkyl or C₁₋₆haloalkyl optionally substituted with one or more OR^a; or

R^d and R^e may, together with the atom to which they are attached, form a 4-, 5- or 6-membered heterocyclic ring containing one or more heteroatoms selected from N, O or S, wherein said heterocyclic ring is optionally substituted with one or more halo, C_{1-3} alkyl or C_{1-3} haloalkyl, said C_{1-3} alkyl or C_{1-3} haloalkyl optionally further substituted with one or more C_{1-3} alkoxy;

R^h is hydrogen, C_{1-3} alkyl or C_{1-3} haloalkyl, said C_{1-3} alkyl or C_{1-3} haloalkyl optionally substituted with one or more C_{1-3} alkoxy;

R^i is C_{1-3} alkyl or C_{1-3} haloalkyl, said C_{1-3} alkyl or C_{1-3} haloalkyl optionally substituted with one or more OR^a ; and

R^j is an aryl or heteroaryl ring, wherein said aryl or heteroaryl ring is optionally substituted with one or more C_{1-3} alkyl, OR^a , halo or CN; or a pharmaceutically acceptable salt thereof for use in the manufacturing of a medicament for prevention and/or treatment of Alzheimer's Disease.

2. The use of according to claim 1, wherein

R^1 is selected from hydrogen, $SO_2NR^bR^c$, $C(O)NR^bR^c$, $CH_2NR^bR^c$ and $C(O)R^j$;

R^2 and R^4 are independently selected from hydrogen, halo, CN, C_{1-3} alkyl, OR^a , and SO_2R^i ;

R^3 and R^5 independently are selected from hydrogen, C_{1-3} alkyl, C_{1-3} haloalkyl;

R^6 is selected from C_{2-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, and C_{2-4} haloalkyl;

R^7 is C_{1-3} alkyl;

R^8 and R^9 are independently selected from hydrogen and halo; and

R^a is C_{1-3} alkyl or C_{1-3} haloalkyl, said C_{1-3} alkyl or C_{1-3} haloalkyl optionally substituted with one or more C_{1-3} alkoxy;

R^b and R^c are independently selected from hydrogen, C_{1-6} alkyl or C_{1-6} haloalkyl, said C_{1-6} alkyl or C_{1-6} haloalkyl optionally substituted with one or more OR^a ; or

R^b and R^c may, together with the atom to which they are attached, form a 4-, 5- or 6-membered heterocyclic ring containing one or more heteroatoms selected from N, O or S, wherein said heterocyclic ring is optionally substituted with one or more halo, C_{1-3} alkyl or

C₁₋₃haloalkyl, said C₁₋₃alkyl or C₁₋₃haloalkyl optionally further substituted with one or more C₁₋₃alkoxy;

Rⁱ is C₁₋₃alkyl; and

R^j is aryl or heteroaryl;

5 or a pharmaceutically acceptable salt thereof.

3. The use according to claim 1 or 2, wherein

R¹ is selected from SO₂NR^bR^c, C(O)NR^bR^c and C(O)Rⁱ;

R² and R⁴ are independently selected from hydrogen, halo, CN, C₁₋₃alkyl, OR^a, and SO₂Rⁱ;

10 R³ and R⁵ independently are selected from hydrogen, C₁₋₃alkyl, C₁₋₃haloalkyl;

R⁶ is C₂₋₄alkyl;

R⁷ is C₁₋₃alkyl;

R⁸ and R⁹ are independently selected from hydrogen and halo;

R^a is C₁₋₃alkyl or C₁₋₃haloalkyl;

15 R^b and R^c may, together with the atom to which they are attached, form a 4-, 5 or 6-membered heterocyclic ring containing one or more heteroatoms selected from N, O or S, wherein said heterocyclic ring is optionally substituted with one or more C₁₋₃alkyl;

Rⁱ is C₁₋₃alkyl; and

R^j is aryl or heteroaryl;

20 or a pharmaceutically acceptable salt thereof.

4. The use according to claim 1, wherein R⁹ is halo and R⁸ is hydrogen.

5. The use according to claim 4, wherein R⁹ is fluoro.

25

6. The use according to claim 4 or claim 5, wherein R⁶ is C₂₋₄alkyl.

7. The use according to claim 6, wherein R⁶ is isopropyl.

8. The use according to any one of claims 4 to 7, wherein R^7 is fluoromethyl or methyl.

9. The use according to any one of claims 4 to 8, wherein R^2 and R^4 are hydrogen.

5

10. The use according to any one of claims 4 to 9, wherein R^5 and R^3 are hydrogen.

11. The use according to any one of claims 4 to 10, wherein R^1 is selected from $C(O)NR^bR^c$, $SO_2R^bR^c$, SO_2R^i or $C(O)R^j$.

10

12. The use according to claim 11, wherein R^j is phenyl or piperidin.

13. The use according to claim 11, wherein R^b and R^c , together with the atom to which they are attached, form a 6-membered heterocyclic ring containing one or more

15

heteroatoms selected from N, wherein said heterocyclic ring is optionally substituted with one or more halo, C_{1-3} alkyl or C_{1-3} haloalkyl.

14. The use according to claim 13, wherein said heterocyclic ring is substituted with one or more C_{1-3} alkyl.

20

15. The use according to claim 14, wherein said C_{1-3} alkyl is methyl.

16. The use according to claim 11, wherein R^i is C_{1-3} alkyl.

25

17. The use according to claim 11, wherein R^i is methyl,

18. The use according to claim 1, said compound being selected from:
(4-{[5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-yl]amino}phenyl)(phenyl)methanone hydrochloride;

(4-{[5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-yl]amino}phenyl)(pyridin-2-yl)methanone hydrochloride;

(4-{[5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-yl]amino}phenyl)(pyridin-3-yl)methanone hydrochloride;

5 5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-*N*-{3-methyl-4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrimidin-2-amine hydrochloride;

5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-*N*-{2-methyl-4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrimidin-2-amine hydrochloride;

10 5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-*N*-[4-[(4-methylpiperazin-1-yl)sulfonyl]-2-(trifluoromethyl)phenyl]pyrimidin-2-amine hydrochloride;

5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-*N*-[4-[(4-methylpiperazin-1-yl)sulfonyl]-3-(trifluoromethoxy)phenyl]pyrimidin-2-amine hydrochloride;

5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-*N*-[4-[(4-methylpiperazin-1-yl)carbonyl]-3-(methylsulfonyl)phenyl]pyrimidin-2-amine hydrochloride;

15 5-{[5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-yl]amino}-2-[(4-methylpiperazin-1-yl)carbonyl]benzonitrile hydrochloride;

N-{3-Chloro-4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}-5-fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-amine hydrochloride;

20 5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-*N*-{3-methoxy-4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}pyrimidin-2-amine hydrochloride;

(4-{[5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-yl]amino}phenyl)(pyridin-4-yl)methanone hydrochloride;

5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-*N*-{4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}pyrimidin-2-amine hydrochloride;

25 5-Fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-*N*-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrimidin-2-amine hydrochloride;

5-Fluoro-4-[1-isopropyl-2-(trifluoromethyl)-1*H*-imidazol-5-yl]-*N*-[4-(methylsulfonyl)phenyl]pyrimidin-2-amine hydrochloride;

30 5-Fluoro-4-[1-isopropyl-2-(trifluoromethyl)-1*H*-imidazol-5-yl]-*N*-[4-(methylsulfonyl)phenyl]pyrimidin-2-amine hydrochloride;

{4-[5-Fluoro-4-(3-isopropyl-2-trifluoromethyl-3*H*-imidazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone hydrochloride; and

3-{[5-Fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino}-N-(3-methoxypropyl)benzamide hydrochloride;
or a pharmaceutically acceptable salt thereof.

- 5 19. A pharmaceutical formulation for use in the treatment and/or prophylaxis of Alzheimer's Disease, comprising a therapeutically effective amount of a compound of formula I as defined in any one of claims 1 to 18 or a pharmaceutically acceptable salt thereof and conventional excipients.
- 10 20. A method of treatment and/or prophylaxis of Alzheimer's Disease comprising administering to a mammal, including man in need of such treatment and/or prophylaxis a therapeutically effective amount of a compound of formula I as defined in any one of claims 1 to 18 or a pharmaceutically acceptable salt thereof.
- 15 21. A compound selected from:
1-[4-Bromo-2-(methylsulfonyl)benzoyl]-4-methylpiperazine;
1-(4-Chloro-2-iodobenzoyl)-4-methylpiperazine;
5-Chloro-2-[(4-methylpiperazin-1-yl)carbonyl]benzonitrile;
1-(4-Chloro-2-methoxybenzoyl)-4-methylpiperazine;
20 2,2,2-Trifluoro-N-isopropyl-N-(5-methyl-isoxazol-4-yl)-acetamide;
5-Acetyl-2-trifluoromethyl-1-isopropyl-1H-imidazole;
(2E)-3-Dimethylamino-1-(2-trifluoromethyl-1-isopropyl-1H-imidazol-5-yl)prop-2-en-1-one;
(2Z)-3-Dimethylamino-2-fluoro-1-(2-trifluoromethyl-1-isopropyl-1H-imidazol-5-yl)prop-
25 2-en-1-one; and
5-Fluoro-4-[2-trifluoromethyl-1-isopropyl-1H-imidazol-5-yl]pyrimidin-2-amine;
Methyl 3-{[5-fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino}benzoate.
- 30 22. Use of the compounds according to claim 21 in the preparation of a compound of formula I as defined in claim 1.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE2006/001112**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 20
because they relate to subject matter not required to be searched by this Authority, namely:
Claim 20 relates to a method of treatment of the human or animal body by surgery or by therapy, as well as diagnostic
.../...
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

The following separate inventions were identified:

1: Claims 1-20 directed to the use of compound I and part of claims 21-22 directed to the intermediate compounds methyl 3-{[5-fluoro-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-
.../...

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-20 and part of claims 21-22

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

Box II.1

methods /Rule 39.1(iv). Nevertheless, a search has been executed for this claim. The search has been based on the alleged effects of the compounds.

Box III

2-yl]amino}benzoate and 5-fluoro-4-[2-trifluoromethyl-1-isopropyl-1H-imidazole-5-yl]-pyrimidine-2-amine (compound 9-10).

2: Part of claims 21-22 directed to the intermediate compounds with a benzoyl-4-methylpiperazine group (compounds 1-4).

3: Part of claims 21-22 directed to the intermediate compound 2,2,2-trifluoro-N-isopropyl-N-(5-methyl-isoxazol-4-yl)-acetamide (compound 5).

4: Part of claims 21-22 directed to the intermediate compounds with a (1-isopropyl-2-trifluoromethyl)-1H-imidazole group (compounds 6-8).

In order to fulfil the requirements of unity of invention, it is necessary that the intermediate compounds are closely interconnected with the end products. Such close connection requires that the essential structural part of the end product is incorporated by the intermediate compound. However, the present application lacks a single general inventive concept based on the above principle.

The present application has been considered to contain 4 inventions which are not linked such that they form a single general inventive concept, as required by Rule 13 PCT.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE2006/001112

A. CLASSIFICATION OF SUBJECT MATTER

IPC: see extra sheet

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC: A61K, C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, PAJ, CHEM.ABS DATA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 03076434 A1 (ASTRAZENECA AB), 18 Sept 2003 (18.09.2003), examples 15-22,25-30,37-38,57,62,64, 69,76 --	19
X	WO 03076436 A1 (ASTRAZENECA AB), 18 Sept 2003 (18.09.2003), examples 3-5,21-23,30,37,39-41,44-47, 54-55,58-61,65-66,68-69 --	19
X	WO 0220512 A1 (ASTRAZENECA UK LIMITED), 14 March 2002 (14.03.2002), examples 37,42-43,45, 52-53 --	19

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

20 February 2007

Date of mailing of the international search report

21-02-2007

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Helena Melander/ELY

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE2006/001112

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2005012298 A1 (CYCLACELL LIMITED), 10 February 2005 (10.02.2005) --	1-20, 21-22(PARTLY)
A	WO 2004056368 A1 (CYCLACEL LIMITED), 8 July 2004 (08.07.2004) --	1-20, 21-22(PARTLY)
A	WO 2004083203 A1 (VERTEX PHARMACEUTICALS INCORPORATED), 30 Sept 2004 (30.09.2004) --	1-20, 21-22(PARTLY)
A	WO 2004072063 A1 (VERTEX PHARMACEUTICALS INCORPORATED), 26 August 2004 (26.08.2004) --	1-20, 21-22(PARTLY)
A	WO 02066480 A2 (ASTRAZENECA AB), 29 August 2002 (29.08.2002) --	1-20, 21-22(PARTLY)
A	WO 02065979 A2 (ASTRAZENECA AB), 29 August 2002 (29.08.2002) --	1-20, 21-22(PARTLY)
A	WO 03037891 A1 (JANSEN PHARMACEUTICA N.V.), 8 May 2003 (08.05.2003) -- -----	1-20, 21-22(PARTLY)

International patent classification (IPC)

A61K 31/506 (2006.01)
A61P 19/08 (2006.01)
A61P 25/16 (2006.01)
A61P 25/18 (2006.01)
A61P 25/24 (2006.01)
A61P 25/28 (2006.01)
A61P 3/10 (2006.01)
C07D 401/14 (2006.01)
C07D 403/04 (2006.01)

Download your patent documents at www.prv.se

The cited patent documents can be downloaded at www.prv.se by following the links:

- In English/Searches and advisory services/Cited documents (service in English) or
- e-tjänster/anförda dokument(service in Swedish).

Use the application number as username.

The password is **WJAFQOFANU**.

Paper copies can be ordered at a cost of 50 SEK per copy from PRV InterPat (telephone number 08-782 28 85).

Cited literature, if any, will be enclosed in paper form.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/SE2006/001112

WO 03076434 A1 18/09/2003

AU	2002366304	A	00/00/0000
AU	2003208479	A	00/00/0000
BR	0215190	A	16/11/2004
CA	2470651	A	26/06/2003
EP	1465689	A	13/10/2004
EP	1490354	A	29/12/2004
GB	0205695	D	00/00/0000
HR	20040563	A	31/12/2004
HU	0500003	A	30/05/2005
IL	162586	D	00/00/0000
JP	2005511252	T	28/04/2005
JP	2005524672	T	18/08/2005
MX	PA04005897	A	31/03/2005
US	20060074096	A	06/04/2006
GB	0217633	D	00/00/0000

WO 03076436 A1 18/09/2003

AU	2002350967	A	00/00/0000
AU	2003214394	A	00/00/0000
BR	0308212	A	21/12/2004
CA	2478701	A	18/09/2003
CN	1649863	A	03/08/2005
EP	1463446	A	06/10/2004
EP	1487823	A	22/12/2004
GB	0205693	D	00/00/0000
IL	163910	D	00/00/0000
IS	7439	A	07/09/2004
JP	3569524	B	22/09/2004
JP	2004256550	A	16/09/2004
JP	2005512720	T	12/05/2005
JP	2005519135	T	30/06/2005
MX	PA04008807	A	26/11/2004
NO	20043851	A	14/09/2004
PL	372703	A	25/07/2005
RU	2004130440	A	10/05/2005
US	20050131000	A	16/06/2005
US	20050154438	A	14/07/2005
ZA	200406937	A	22/02/2006

International application No.

PCT/SE2006/001112

WO	0220512	A1	14/03/2002	AT	269327	T	15/07/2004
				AU	8419201	A	22/03/2002
				BG	107579	A	31/10/2003
				BR	0113496	A	01/07/2003
				CA	2417148	A	14/03/2002
				CN	1269813	C	16/08/2006
				CN	1452620	A,T	29/10/2003
				CZ	20030617	A	18/06/2003
				DE	60103935	D,T	21/07/2005
				DK	1351958	T	06/09/2004
				EE	200300088	A	15/02/2005
				EP	1351958	A,B	15/10/2003
				SE	1351958	T3	
				ES	2221904	T	16/01/2005
				GB	0021726	D	00/00/0000
				HK	1057553	A	31/12/2004
				HU	0302922	A	29/12/2003
				IL	154292	D	00/00/0000
				IS	2055	B	14/10/2005
				IS	6715	A	12/02/2003
				JP	2004508365	T	18/03/2004
				MX	PA03001511	A	09/06/2003
				NO	20031006	A	04/03/2003
				NZ	523787	A	24/09/2004
				PL	360627	A	20/09/2004
				PT	1351958	T	30/09/2004
				RU	2284327	C	27/09/2006
				SI	1351958	T	31/10/2004
				SK	2412003	A	11/09/2003
				TW	242559	B	01/11/2005
				US	6969714	B	29/11/2005
				US	20040014776	A	22/01/2004
				US	20060004033	A	05/01/2006
				ZA	200300612	A	22/04/2004
WO	2005012298	A1	10/02/2005	AU	2004261482	A	10/02/2005
				BR	PI0412351	A	05/09/2006
				CA	2533870	A	10/02/2005
				CN	1835949	A	20/09/2006
				EP	1648887	A	26/04/2006
				GB	0317842	D	00/00/0000
				US	20060241297	A	26/10/2006
				GB	0318347	D	00/00/0000
WO	2004056368	A1	08/07/2004	AU	2003292444	A	00/00/0000
				BR	0316703	A	18/10/2005
				CA	2502138	A	08/07/2004
				CN	1720049	A	11/01/2006
				EP	1572211	A	14/09/2005
				GB	0229581	D	00/00/0000
				JP	2006515588	T	01/06/2006
				MX	PA05006515	A	08/09/2005
				US	20050282843	A	22/12/2005

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/SE2006/001112

WO	2004083203	A1	30/09/2004	AU	2004221881 A	30/09/2004
				CA	2522176 A	30/09/2004
				EP	1606284 A	21/12/2005
				JP	2006520386 T	07/09/2006
				US	20040220200 A	04/11/2004
				US	20040244126 A	09/12/2004

WO	2004072063	A1	26/08/2004	AU	2004212421 A	26/08/2004
				CA	2515132 A	26/08/2004
				EP	1611125 A	04/01/2006
				JP	2006518381 T	10/08/2006
				US	20040214928 A	28/10/2004
				US	20040006213 A	08/01/2004

WO	02066480	A2	29/08/2002	BR	0207096 A	20/01/2004
				CA	2435177 A	29/08/2002
				CN	1823064 A	23/08/2006
				EP	1423388 A	02/06/2004
				IL	156784 D	00/00/0000
				JP	2004522777 T	29/07/2004
				MX	PA03007266 A	04/12/2003
				NO	20033677 A	02/10/2003
				NZ	527009 A	28/04/2006
				US	7078410 B	18/07/2006
				US	20040106574 A	03/06/2004
				ZA	200306175 A	08/11/2004

WO	02065979	A2	29/08/2002	AU	4295101 A	03/10/2001
				BG	108070 A	30/07/2004
				BR	0206935 A	29/06/2004
				CA	2434648 A	29/08/2002
				CN	1294131 C	10/01/2007
				CN	1537112 A	13/10/2004
				CZ	20032235 A	14/01/2004
				EE	200300400 A	15/12/2003
				EP	1373266 A	02/01/2004
				HU	0303254 A	28/01/2004
				IL	156781 D	00/00/0000
				IS	6868 A	08/07/2003
				JP	2004527486 T	09/09/2004
				MX	PA03007320 A	04/12/2003
				NO	20033679 A	19/08/2003
				NZ	526783 A	29/04/2005
				PL	363393 A	15/11/2004
				RU	2003121307 A	27/02/2005
				SE	0100569 D	00/00/0000
				SK	10252003 A	03/02/2004
				US	20040077642 A	22/04/2004
				ZA	200306171 A	08/11/2004

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/SE2006/001112

WO	03037891	A1	08/05/2003	BR	0213792 A	07/12/2004
				CA	2463822 A	08/05/2003
				CN	1582285 A	16/02/2005
				EP	1448556 A	25/08/2004
				HU	0402106 A	28/02/2005
				IL	161662 D	00/00/0000
				JP	2005507423 T	17/03/2005
				MX	PA04004178 A	06/09/2004
				NO	20041911 A	10/05/2004
				NZ	531853 A	24/02/2006
				PL	369259 A	18/04/2005
				US	20050004125 A	06/01/2005
